3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases

ABSTRACT

Compounds which are 4,7-disubstituted derivatives of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds with the formula 
                         
or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

BACKGROUND OF THE DISCLOSURE

The present invention relates to certain 4,7-disubstituted derivatives of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds, which modulate the activity of protein kinases. The compounds of this invention are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also relates to methods for preparing these compounds, combinatorial libraries thereof, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. The malfunctioning of protein kinases (PKs) is the hallmark of numerous diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers code for PKs. The enhanced activities of PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.

PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders.

For general reference to PKs malfunctioning or disregulation see, for instance, Current Opinion in Chemical Biology 1999, 3, 459-465 and Carcinogenesis 2008, 29, 1087-191.

8-Hydroxy-3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for prevention and treatment of infection by HIV and in the prevention, delay in the onset and treatment of AIDS are disclosed in WO 2004/047725 in the name of Merck & Co., Inc., USA. The present inventors have now discovered that the new compounds of formula (I), described below, are kinase inhibitors and are thus useful in therapy as antitumor agents.

BRIEF SUMMARY OF THE DISCLOSURE

Accordingly, a first object of the present invention is to provide a 4,7-disubstituted-3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compound represented by formula (I):

wherein:

-   R1 is a group —NR^(a)R^(b) or —OR^(a) and -   R2 is —NH₂, —NHCOR^(c), —NHCONHR^(c), —NHSO₂R^(c), —C≡CR^(d) or     R^(d), -   wherein R^(a), R^(b), R^(c) and R^(d), the same or different, are     each independently hydrogen or a group optionally further     substituted, selected from straight or branched C₁-C₆ alkyl, C₂-C₆     alkenyl or C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl,     heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl,     heteroaryl and heteroaryl C₁-C₆ alkyl, or R^(a) and R^(b), taken     together with the nitrogen atom to which they are bonded, may form     an optionally substituted 3 to 7 membered heterocyclyl or     heteroaryl, optionally containing one additional heteroatom or     heteroatomic group selected from S, O, N or NH, and pharmaceutically     acceptable salts thereof.

The present invention also provides methods of synthesizing the 4,7-disubstituted-3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds, represented by formula (I), prepared through a process consisting of standard synthetic transformations.

The present invention also provides a method for treating diseases caused by and/or associated with dysregulated protein kinase activity, particularly PLK family, ABL, AKT1, ALK, AUR1, AUR2, BRK, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EE2FK, EGFR1, ERK2, FAK, FGFR1, FLT3, GSK3beta, IGFR1, IKK2, IR, JAK2, JAK3, KIT, LCK, MAPKAPK2, MET, MPS1, MST4, NEK6, NIM1, P38alpha, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PIM3, PKAalpha, PKCbeta, PLK1, RET, SULU1, SYK, TRKA, VEGFR2, VEGFR3 or ZAP70.

A preferred method of the present invention is to treat a disease caused by and/or associated with dysregulated protein kinase activity selected from the group consisting of cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders.

Another preferred method of the present invention is to treat specific types of cancer including but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukaemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Another preferred method of the present invention is to treat specific cellular proliferation disorders such as, for example, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.

The compounds of this invention may be useful in inhibiting tumour angiogenesis and metastasis, as well as in the treatment of organ transplant rejection and host versus graft disease.

The present invention further provides a method of treatment comprising a compound of formula (I) in combination with radiation therapy or chemotherapy regimen for simultaneous, separate or sequential use in anticancer therapy.

Moreover the invention provides a method for inhibiting protein kinase activity which comprises contacting the said protein kinase with an effective amount of a compound of formula (I).

The present invention also provides a pharmaceutical composition comprising one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, carrier or diluent.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I) in combination with known cytostatic or cytotoxic agents, antibiotic-type agents, DNA damaging or intercalating agents, platin-based agents, alkylating agents, antimetabolite agents, hormonal agents, antihormonal agents such as antiestrogens, antiandrogens and aromatase inhibitors, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, tyrosine kinase inhibitors, other kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, inhibitors of kinesins, therapeutic monoclonal antibodies, inhibitors of mTOR, histone deacetylase inhibitors, inhibitors of hypoxic response and the like, for simultaneous, separate or sequential use in anticancer therapy.

Additionally, the invention provides a product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, or pharmaceutical compositions thereof and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

In yet another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use as a medicament.

Moreover the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, in the manufacture of a medicament with antitumor activity.

Finally, the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use in a method of treating cancer.

DETAILED DESCRIPTION OF THE DISCLOSURE

Unless otherwise specified, when referring to the compounds of formula (I) per se as well as to any pharmaceutical composition thereof or to any therapeutic method of treatment comprising them, the present invention includes all the hydrates, solvates, complexes, metabolites, prodrugs, carriers, N-oxides and pharmaceutically acceptable salts of the compounds of this invention.

A metabolite of a compound of formula (I) is any compound into which this same compound of formula (I) is converted in vivo, for instance upon administration to a mammal in need thereof. Typically, without however representing a limiting example, upon administration of a compound of formula (I), this same derivative may be converted into a variety of compounds, for instance including more soluble derivatives like hydroxylated derivatives, which are easily excreted. Hence, depending upon the metabolic pathway thus occurring, any of these hydroxylated derivatives may be regarded as a metabolite of the compounds of formula (I).

Prodrugs are any covalently bonded compounds, which release the active parent drug according to formula (I) in vivo.

N-oxides are compounds of formula (I) wherein nitrogen and oxygen are tethered through a dative bond.

All forms of chiral isomers or other forms of isomers including enantiomers and diastereomers, are intended to be covered herein. Compounds containing a chiral center may be used as a racemic mixture or as an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.

In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.

In the present description, unless otherwise indicated, with the term “straight or branched C₁-C₆ alkyl” we intend any group such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.

With the term “straight or branched C₂-C₆ alkenyl” or “straight or branched C₂-C₆ alkynyl” we intend any of the unsaturated alkenyl or alkynyl groups with from 2 to 6 carbon atoms for instance including vinyl, allyl, 1-propenyl, isopropenyl, 1-, 2- or 3-butenyl, pentenyl, hexenyl, ethynyl, 1- or 2-propynyl, butynyl, pentynyl, hexynyl, and the like. With the term “C₃-C₆ cycloalkyl” we intend, unless otherwise specified, 3- to 6-membered all-carbon monocyclic ring, which may contain one or more double bonds but does not have a completely conjugated π-electron system.

Examples of cycloalkyl groups, without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene and cyclohexadiene.

With the term “heterocyclyl” we intend a 3- to 7-membered, saturated or partially unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen and sulfur. Non limiting examples of heterocyclyl groups are, for instance, pyrane, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine, morpholine and the like.

With the term “aryl” we intend a mono-, bi- or poly-carbocyclic hydrocarbon with from 1 to 4 ring systems, optionally further fused or linked to each other by single bonds, wherein at least one of the carbocyclic rings is “aromatic”, wherein the term “aromatic” refers to completely conjugated π-electron bond system. Non-limiting examples of such aryl groups are phenyl, α- or β-naphthyl or biphenyl groups.

With the term “heteroaryl” we intend aromatic heterocyclic rings, typically 5- to 7-membered heterocycles with from 1 to 3 heteroatoms selected among N, O or S; the heteroaryl ring can be optionally further fused or linked to aromatic and non-aromatic carbocyclic and heterocyclic rings. Not limiting examples of such heteroaryl groups are, for instance, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, pyrrolyl, phenyl-pyrrolyl, furyl, phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl, quinolinyl, isoquinolinyl, 1,2,3-triazolyl, 1-phenyl-1,2,3-triazolyl, 2,3-dihydroindolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl; benzopyranyl, 2,3-dihydrobenzoxazinyl, 2,3-dihydroquinoxalinyl and the like.

According to the meanings provided to R^(a), R^(b), R^(c) and R^(d), any of the above groups may be further optionally substituted in any of their free positions by one or more groups, for instance 1 to 6 groups, selected from: halogen, nitro, oxo groups (═O), carboxy, cyano, C₁-C₆ alkyl, polyfluorinated alkyl, C2-06 alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, heterocyclyl, aryl, heteroaryl; amino groups and derivatives thereof such as, for instance, alkylamino, dialkylamino, arylamino, diarylamino, ureido, alkylureido or arylureido; carbonylamino groups and derivatives thereof such as, for instance, formylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino; hydroxy groups and derivatives thereof such as, for instance, alkoxy, polyfluorinated alkoxy, aryloxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy or alkylideneaminoxy; carbonyl groups and derivatives thereof such as, for instance, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl; sulfurated derivatives such as, for instance, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, arylsulfonyloxy, aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl.

In their turn, whenever appropriate, each of the above substituents may be further substituted by one or more of the aforementioned groups.

In the present description, unless otherwise specified, with the term “cyano” we intend a —CN residue.

-   With the term “nitro” we intend a —NO₂ group. -   With the term “halogen” we intend a fluorine, chlorine, bromine or     iodine atom. -   With the term “polyfluorinated alkyl or alkoxy” we intend a straight     or branched C₁-C₆ alkyl or alkoxy group as above defined, wherein     more than one hydrogen atom is replaced by fluorine atoms such as,     for instance, trifluoromethyl, trifluoromethoxy,     2,2,2-trifluoroethyl, 2,2,2-trifluoroethoxy, 1,2-difluoroethyl,     1,1,1,3,3,3-hexafluoropropyl-2-yl, and the like.

From all of the above, it is clear to the skilled man that any group which name has been identified as a composite name such as, for instance, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, alkoxy, alkylthio, aryloxy, arylalkyloxy, alkylcarbonyloxy and the like, has to be intended as conventionally construed from the parts to which it derives. So far, as an example, the terms heterocyclyl-alkyl and cycloalkyl-alkyl stand for a straight or branched alkyl group being further substituted by a heterocyclic or cycloalkyl group, respectively, as above defined.

The term “pharmaceutically acceptable salts” embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, trifluoroacetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, hydroxybutyric, galactaric and galacturonic acid. Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compounds of the present invention, for instance by reacting them with the appropriate acid or base.

A preferred class of compounds of formula (I) are the compounds wherein:

-   R1 is a group —NR^(a)R^(b) and R^(a) and R^(b) are both hydrogen     atoms or one of them is a hydrogen atom and the remaining one of     R^(a) or R^(b) is a straight or branched C₁-C₆ alkyl or C₂-C₆     alkenyl group or it is an optionally substituted aryl or aryl C₁-C₆     alkyl group.

Another preferred class of compounds of formula (I) are the compounds wherein:

-   R2 is a group —NHCOR^(c) wherein R^(c) is as defined before.

A further preferred class of compounds of formula (I) are the compounds wherein:

-   R2 is a group —NHCONHR^(c) wherein R^(c) is as defined before.

A more preferred class of compounds of formula (I) are the compounds wherein:

-   R2 is a group —NHSO₂R^(c) wherein R^(c) is as defined before.

For a reference to any specific compound of formula (I) of the invention, optionally in the form of pharmaceutically acceptable salts, see the experimental section.

The present invention also provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the process comprises:

-   a) nitrating under acidic conditions the compound of formula (II):

-   b) reacting the resultant compound of formula (III):

-   with an ammonium salt of formula (IV):

-   wherein R^(a) is C₁-C₆ alkyl; -   optionally converting the resultant compound of formula (V):

wherein R1 represents OR^(a) and R^(a) is as defined above, into another compound of formula (V) wherein R1 is as above defined by replacing —OR^(a) group with a different R1 group,

-   c) reducing said compound of formula (V) to give a compound of     formula (I) or a salt thereof:

wherein R1 is as defined above, and R2 is NH₂;

optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) by derivatizing the amino moiety, and/or by replacing the group —OR^(a) with a different group which R1 represents, and/or converting it into a pharmaceutically acceptable salt if desired.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) is converted into another compound of formula (I), said conversion being carried out by one or more of the following reactions:

-   d) reacting a compound of formula (I) wherein R1 is —OR^(a) and     R^(a) is C₁-C₆ alkyl, and R2 is NH₂ according to any one of the     alternative steps: -   d.1) with an acid or an acyl halide of formula (VI):     R^(c)COZ  (VI) -   wherein R^(c) is as defined above and Z is a halogen or a group —OH,     to give a compound of formula (I):

wherein R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl and R^(c) is as defined above; or

d.2) with an isocyanate of formula (VII): R^(c)NCO   (VII)

-   wherein R^(c) is as defined above, to give a compound of formula     (I):

-   wherein R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl and R^(c) is as     defined above; or -   d.3) with a sulphonyl halide of formula (VIII):     R^(c)SO₂Z′  (VIII) -   wherein R^(c) is as defined above and Z′ is a halogen, to give a     compound of formula (I):

wherein R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl and R^(c) is as defined above,

optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) by replacing the group —OR^(a) with a different group which R1 represents, and/or into a pharmaceutically acceptable salt if desired.

The present invention also provides another process for the preparation of a compound of formula (XI), characterized in that the process comprises:

-   e) iodination of the compound of formula (II):

-   f) reacting the resultant compound of formula (IX):

-   with an ammonium salt of formula (IV):

-   wherein R^(a) is C₁-C₆ alkyl; -   g) cyclizing under basic conditions the resultant compound of     formula (X):

-   wherein R^(a) is as defined above, to give the compound of formula     (XI):

-   wherein R^(a) is as defined above;     converting it into a different compound of formula (XI) by replacing     the Iodo with a different group that R2 represents, optionally     separating it into the single isomers, converting it into a     different compound of formula (XI) by replacing the —OR^(a) group     with a different group which R1 represents and/or into a     pharmaceutically acceptable salt if desired.

The present inventions further provides a process for the preparation of compounds of formula (I) as defined above, characterized in that the process comprises:

-   h) reacting a compound of formula (XI) wherein R1 is —OR^(a) and     R^(a) is C₁-C₆ alkyl, according to any one of the alternative steps: -   h.1) with a boronic acid or ester of formula (XII):     R2′B(OZ″Z′″)₂   (XII) -   wherein R2′ is R^(d) and R^(d) is as defined above, Z″ and Z′″ are     either H, alkyl or, taken together with the oxygen atoms to which     they are bonded, may form an optionally substituted 5 to 6 membered     heterocycle, to give a compound of formula (I):

-   wherein R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl and R2′ is as defined     above; or -   h.2) with a terminal alkyne of formula (XIII):     R^(d)C≡CH   (XIII) -   wherein R^(d) is as defined above, to give a compound of formula     (I):

-   wherein R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl and R^(d) is as     defined above, optionally separating the resultant compound of     formula (I) into the single isomers; converting the resultant     compound of formula (I) into a different compound of formula (I) by     replacing the group —OR^(a) with a different group which R1     represents, and/or into a pharmaceutically acceptable salt if     desired.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) is converted into another compound of formula (I), said conversion is carried out by one or more of the following reactions:

-   m.1) acid or basic hydrolysis of a compound of formula (I), wherein     R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl, to give the corresponding     compound of formula (I) wherein R1 is —OR^(a) and R^(a) is hydrogen,     or the corresponding salt; -   m.2) transesterification of a compound of formula (I) wherein R1 is     —OR^(a) and R^(a) is C₁-C₆ alkyl, by reactions with a compound of     formula (XIV):     R^(a)—OH  (XIV) -   to give the corresponding compound of formula (I) wherein R1 is     —OR^(a) and R^(a) is a different C₁-C₆ alkyl; -   m.3) aminolysis of a compound of formula (I) wherein R₁ is —OR^(a)     and R^(a) is C₁-C₆ alkyl, by reaction with a compound of formula     (XV):     HNR^(a)R^(b)  (XV) -   to give the corresponding compound of formula (I) wherein R1 is     —NR^(a)R^(b); -   m.4) esterification of a compound of formula (I) wherein R1 is a     group —OH or its corresponding salt, by reactions with a compound of     formula (XIV) as defined above, to give the corresponding compound     of formula (I) wherein R1 is —OR^(a), -   m.5) amidation of a compound of formula (I) wherein R1 is a group     —OH or its corresponding salt, by reaction with a compound of     formula (XV) as defined above, to give the corresponding compound of     formula (I) wherein R1 is —NR^(a)R^(b).

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (V) as defined above, is converted into another compound of formula (V), said conversions are carried out by one or more of the following reactions:

-   n.1) acid or basic hydrolysis of a compound of formula (V) wherein     R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl, to give a compound of     formula (V) wherein R1 is —OR^(a) and R^(a) is hydrogen, or the     corresponding salt; -   n.2) transesterification of a compound of formula (V) wherein R1 is     —OR^(a) and R^(a) is C₁-C₆ alkyl, by reaction with a compound of     formula (XIV) as defined above, to give a compound of formula (V)     wherein R1 is —OR^(a) and R^(a) is a different C₁-C₆ alkyl; -   n.3) amidation of a compound of formula (V) wherein R1 is —OR^(a)     and R^(a) is C₁-C₆ alkyl, by reaction with a compound of     formula (XV) as defined above, to give a compound of formula (V)     wherein R1 is —NR^(a)R^(b), -   n.4) esterification of a compound of formula (V) wherein R1 is     —OR^(a) and R^(a) is hydrogen, or the corresponding salt, by     reaction with a compound of formula (XVI) as defined above, to give     a compound of formula (V) wherein R1 is —OR^(a) and R^(a) is     different from hydrogen; -   n.5) amidation of a compound of formula (V) wherein R1 is —OR^(a)     and R^(a) is hydrogen, by reaction with a compound of formula (XV)     as defined above, to give a compound of formula (V) wherein R1 is     —NR^(a)R^(b).

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (XI) as defined above, is converted into another compound of formula (XI), said conversions are carried out by one or more of the following reactions:

-   o.1) acid or basic hydrolysis of a compound of formula (XI) wherein     R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl, to give a compound of     formula (XI) wherein R1 is —OR^(a) and R^(a) is hydrogen, or the     corresponding salt; -   o.2) transesterification of a compound of formula (XI) wherein R1 is     —OR^(a) and R^(a) is C₁-C₆ alkyl, by reaction with a compound of     formula (XIV) as defined above, to give a compound of formula (XI)     wherein R1 is —OR^(a) and R^(a) is a different C1-C₆ alkyl; -   o.3) amidation of a compound of formula (XI) wherein R1 is —OR^(a)     and R^(a) is C₁-C₆ alkyl, by reaction with a compound of     formula (XV) as defined above, to give a compound of formula (XI)     wherein R1 is —NR^(a)R^(b); -   o.4) esterification of a compound of formula (XI) wherein R1 is     —OR^(a) and R^(a) is hydrogen, or the corresponding salt, by     reaction with a compound of formula (XVI) as defined above, to give     a compound of formula (XI) wherein R1 is —OR^(a) and R^(a) is     different from hydrogen; -   o.5) amidation of a compound of formula (XI) wherein R1 is —OR^(a)     and R^(a) is hydrogen, by reaction with a compound of formula (XV)     as defined above, to give a compound of formula (XI) wherein R1 is     —NR^(a)R^(b).

From all of the above, it is clear to the skilled person that if a compound of formula (I), (V), or (XI) prepared according to the above processes comprehensive of any variant thereof, is obtained as an admixture of isomers, their separation into the single isomers of formula (I), carried out according to conventional techniques, is still within the scope of the present invention.

Likewise, the conversion of a compound of formula (I) into a pharmaceutically acceptable salt thereof or, alternatively, the conversion into the free compound (I) of a corresponding salt, according to procedures well-known in the art, is still within the scope of the invention.

When preparing the compounds of formula (I) according to any variant of the process, which are all to be intended as within the scope of the invention, optional functional groups within the starting materials, the reagents or the intermediates thereof, and which could give rise to unwanted side reactions, need to be properly protected according to conventional techniques.

The starting materials of the process object of the present invention, comprehensive of any possible variant, as well as any reactant thereof, are known compounds and if not commercially available per se may be prepared according to well-known methods.

For example, the compound of formula (II) is commercially available.

The compounds of formula (IV) are prepared starting from the corresponding 4-bromocrotonates that in their turn are commercially available or can be prepared according to well-known methods.

For example the 4-amino ethylcrotonate is prepared from the ethyl-4-bromo ethylcrotonate (XVI):

-   i) reacting it with commercially available diformylimide sodium salt     (XVII):

-   l) hydrolyzing in acidic conditions the resultant compound of     formula (XVIII):

-   to give the compound of formula (IV) wherein R^(a) is ethyl.

The compounds of formula (VI), (VII), (VIII), (XII), (XIII), (XIV) and (XV) are known or easily obtained according to known methods, for a general reference see: Smith, Michael—March's Advanced Organic Chemistry: reactions mechanisms and structure—5th Edition, Michael B. Smith and Jerry March, John Wiley & Sons Inc., New York (N.Y.), 2001.

The intermediate compound of formula (V):

-   wherein R1 is as defined above, is novel and hence represents a     further object of the invention.

The intermediate compound of formula (XI):

-   wherein R1 is as defined above, is novel and hence represents a     further object of the invention.

According to step (a) of the process, the nitration of the compound of formula (II) under acidic conditions can be carried out in a variety of ways according to conventional methods. Preferably, the reaction is carried out in the presence of nitric acid and acetic anhydride, at a temperature ranging from −40° C. to room temperature and for a time from 6 hours to overnight.

According to step (b) of the process, the conversion of the compound of formula (III) into the corresponding amido derivative of formula (V), can be carried out in a variety of ways according to conventional methods for obtaining amido derivatives from the corresponding α,α,α-trichloroketones. Preferably the reaction is carried out by reaction of an ammonium salt of formula (IV) in the presence of N,N-diisopropylethylamine, using dichloromethane as the solvent.

According to step (c) of the process, the reduction of the nitro group of the compound of formula (V) to give a compound of formula (I) can be carried out in a variety of ways, according to conventional methods for reducing nitro group to the corresponding amino derivative. Preferably the reaction is carried out in the presence of palladium on carbon in ethanol and hydrochloric acid, under an atmosphere of hydrogen at room temperature for a time ranging from 6 to 8 hours.

According to any one of steps (d.1) to (d.3) the preparation of functionalized amino derivatives starting from the corresponding amine can be carried out in a variety of ways, according to conventional methods.

Preferably according to step (d.1) and (d.3) of the process, the compound of formula (I) is dissolved in a suitable solvent such as dichloromethane, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, dioxane or the like, and a suitable base such as triethylamine, N,N-diisopropylethylamine or sodium carbonate is added therein. The compounds of general formula (VI) or (VIII) are then added and the mixture stirred for a time of about 2 hours to about 15 hours, at a temperature ranging from about 20° C. to about 80° C. A suitable catalyst such as dimethylamino pyridine may be optionally used.

Preferably according to step (d.2) of the process, the reaction conditions are the same as above reported for steps (d.1) and (d.3) except that the base may not be required. The compound of general formula (VII) is then added and the mixture stirred as reported above for steps (d.1) and (d.3).

According to step (e) of the process, the iodination of the compound of formula (II) can be carried out in a variety of ways according to conventional methods. Preferably, the reaction is carried out under neutral conditions in the presence of iodine and silver trifluoroacetate, at a temperature ranging from 0° C. to 18° C. and for a time from 5 hours to overnight.

According to step (f) of the process, the conversion of the compound of formula (IX) into the corresponding amido derivative of formula (X), can be carried out in a variety of ways, according to conventional methods for obtaining amido derivatives from the corresponding α,α,α-trichloroketones. Preferably, the reaction is carried out as described under step (b).

According to step (g) of the process, the cyclization of the compound of formula (X) into the corresponding derivative of formula (XIa) can be carried out in a variety of ways according to conventional methods. Preferably, the reaction is carried out using a base such as diaza(1,3)bicyclo[5.4.0]undecane and acetonitrile as the solvent.

According to any one of steps (h.1) and (h.2) the conversion of a compound of formula (XIa) into a compound of formula (I) can be carried out in a variety of ways, according to conventional methods.

Preferably the reaction of step (h.1) is carried out through the Suzuki coupling between an organoboronic derivative of formula (XII) and a compound of formula (XIa), to give the corresponding compound of formula (I) in the presence of a Pd-catalyst and a base such as sodium or cesium carbonate, in a mixture of solvents, such as dimethoxyethane and water, at a temperature varying from room temperature to 80° C. and for a time between 4 hours and overnight. Preferably the reaction of step (h.2) is carried out through the Sonogashira coupling between an alkyne derivative of formula (XIII) and a compound of formula (XIa), to give the corresponding compound of formula (I) in the presence of a Pd-catalyst, a base such as triethylamine and an additive such as copper(I) iodide, using N,N-dimethylformamide as the solvent, at room temperature and for a time between 4 hours and overnight.

According to step (i) of the process, the substitution reaction of ethyl-4-bromocrotonate of formula (XVI) with diformylimide sodium salt of formula (XVII) to give a product of formula (XVIII) is carried out in refluxing acetonitrile for a time between 10 hours to overnight.

According to step (l) of the process, the acidic hydrolysis of a compound of formula (XVIII) to give a product of formula (IV) is carried out in a refluxing mixture of ethanol-trifluoroacetic acid for a time between 8 hours and overnight.

According to any one of steps (m.1) to (m.5) the conversion of a compound of formula (I) in another compound of formula (I), can be carried out in a variety of ways, according to conventional methods.

Preferably according to step (m.1) of the process, the hydrolysys of a compound of formula (I) wherein R1 is —OCH₂CH₃, to give the corresponding compound of formula (I) wherein R1 is —OH is carried out under acidic or basic conditions. Preferably, the reaction is carried out as described under step (a). According to the operative conditions being employed, the compound of formula (I) wherein R1 is —OH could be obtained either in its acidic form or, alternatively, as a salt.

Preferably according to step (m.2) of the process, the transesterification of a compound of formula (I) wherein R1 is —OCH₂CH₃, to give the corresponding compound of formula (I) wherein R1 is —OR^(a) and R^(a) is an alkyl different from ethyl, is carried out by reaction with a compound of formula (XV) in an appropriate solvent, such as the compound of formula (XV) itself or dioxane at the refluxing temperature, optionally in the presence of a suitable metal based catalysts, like dibutylin oxide or titanium alkoxides such as, for instance, titanium (IV) ethoxide, titanium (IV) isopropoxide and the like.

Preferably according to step (m.3) of the process, the aminolysis of a compound of formula (I) wherein R1 is —OCH₂CH₃, to give the corresponding compound of formula (I) wherein R1 is —NR^(a)R^(b), is carried out in an appropriate solvent such as dioxane or dichloromethane optionally in the presence of a suitable metal based catalysts, like trimethyl aluminium.

Preferably according to step (m.4) of the process, the esterification of a compound of formula (I) wherein R1 is a group —OH to give the corresponding compound of formula (I) wherein R1 is —OR^(a), is carried out in the presence of a suitable condensing agent, for instance dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (DHBT), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU), benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), or 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), in an appropriate solvent such as dichloromethane (DCM), N,N-dimethylformamide (DMF) or N,N-dimethylacetamide (DMA).

Preferably according to step (m.5) of the process, the amidation of a compound of formula (I) wherein R1 is a group —OH to give the corresponding compound of formula (I) wherein R1 is —NR^(a)R^(b) can be carried out in a variety of ways, according to conventional methods for obtaining amido derivatives from the corresponding acids. Preferably, the reaction is carried out by reaction with compound of formula (XV) after activation of the carboxylic function of the compound of formula (I) by reaction with thionyl chloride, oxalyl chloride or alternatively in the presence of a suitable condensing agent, for instance dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HBTOH), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU) or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), in an appropriate solvent such as dichloromethane, and/or N,N-dimethylformamide or N,N-dimethylacetamide.

According to any one of steps (n.1) to (n.5) the conversion of a compound of formula (V) into another compound of formula (V) can be carried out in a variety of ways, according to conventional methods.

Preferably it is carried out as described under the steps from (m.1) to (m.5).

According to any one of steps (o.1) to (on.5) the conversion of a compound of formula (XI) into another compound of formula (XI) can be carried out in a variety of ways, according to conventional methods.

Preferably it is carried out as described under the steps from (m.1) to (m.5).

In addition to the above, the compounds of formula (I) may be advantageously prepared according to combinatorial chemistry techniques widely known in the art, by accomplishing the aforementioned reactions between the intermediates in a serial manner and by working under solid-phase-synthesis (SPS) conditions.

As an example, the intermediate carboxy ester derivatives of formula (Va) being obtained in step (b) of the above processes, can be first converted into the free carboxy acid derivative by means of hydrolysis carried out according to conventional methods, then easily supported onto a polymeric resin, for instance through the formation of a carboxamido group.

The intermediate thus supported may be subsequently reacted according to the remaining steps of the process.

The above synthetic pathway can be summarized as follows:

-   wherein the resin is a commercially available polystyrenic resin     including, for instance, Wang resin, Trityl resin, Cl-trityl resin,     Rink amide resin, Tentagel OH resin and derivatives thereof, R2″ and     R^(a) are as defined above.

Any of the above reactions is carried out according to known methods, by working as formerly reported, and allows obtaining compounds of formula (I) as set forth above.

According to a preferred embodiment of the invention, the polystyrenic resin is a derivatized formyl polystyrenic resin which may be obtained by reacting a commercially available formyl polystyrenic resin, e.g. 4-(4-formyl-3-methoxyphenoxy)butyryl AM resin, with a suitable amino derivative under reductive conditions, for instance in the presence of sodium triacetoxyborohydride and derivatives thereof, substantially as follows:

The reaction may be carried out in a suitable solvent such as tetrahydrofuran and in the presence of acetic acid.

The polymer-supported-amino derivatives thus obtained, particularly those, which are referable to as derivatized formyl polystyrenic resin above, are widely known in the art.

In general, amines loaded onto formylpolystyrenic resins also known as Acid Sensitive MethoxyBenzaldehyde polystyrene resins (AMEBA resin) are prepared by standard reductive amination in the presence of an excess of amine in TMOF/DCE and NaBH(OAc)3 or AcOH/DMF and NaCNBH₃, for instance as reported in Tetrahedron Letters (1997), 38, 7151-7154; J. Am. Chem. Soc. (1998), 120, 5441; and Chem. Eur. J. (1999), 5, 2787.

Therefore, it is a further object of the present invention a process for preparing the compounds of formula (I), and the pharmaceutically acceptable salts thereof, which process comprises:

-   p) hydrolyzing under acid or basic conditions the compound of     formula (V) wherein R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl; -   r) reacting the resultant acid derivative with a derivatized formyl     polystyrenic resin of formula (XIX):     (P)—CH₂—NHR^(a)  (XIX) -   wherein (P) is the resin and R^(a) is as defined above; -   s) reacting of the resultant compound of formula (XX):

-   wherein (P) and R^(a) are as described above, with a suitable     reducing agent such as chromium (II) chloride, tetrabutylammonium     hydrogen sulfide or tin (II) chloride;

and

-   t) reacting the resultant compound of formula (XXI):

-   wherein (P) and R^(a) are as described above, as described under any     one of steps (d.1) or (d.2); -   u) cleaving the resin under acidic conditions from the resultant     compound of formula (XXII):

-   to give a compound of formula (I), wherein R2″ is —NHCOR^(c) or     —NHCONHR^(c), wherein R^(c) is as defined above, and R1 is —NHR^(a),     wherein R^(a) is as defined above; -   optionally separating the resultant compound of formula (I) into the     single isomers; converting the resultant compound of formula (I)     into a different compound of formula (I) and/or into a     pharmaceutically acceptable salt if desired.

According to step (p) of the process, the hydrolysis of a compound of formula (Va), to give the corresponding compound of formula (V) wherein R1 is —OH is carried out as described under step (m.1).

According to step (r) of the process, the reaction with the polystyrene resin is performed in a suitable solvent, for instance DMF, in the presence of N,N-diisopropylethylamine (DIPEA) and of a suitable condensing agent such as, for instance, benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU).

According to step (s) of the process, the supported compound of formula (XX) is reduced to obtain the corresponding amino derivative; the reaction is carried out in the presence of tin (II) chloride in dimethylformamide (DMF) at room temperature for a time ranging from 4 to 24 hours.

According to step (t), the supported compound of formula (XXI) is optionally further reacted to give to a variety of compounds functionalised in position 4 of the 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one ring, as described under any one of steps from (d.1) and (d.2).

According to step (u), the cleavage of the resin is performed under acidic conditions in the presence of suitable acids such as, for instance, hydrochloric, trifluoroacetic, methanesulfonic or p-toluensulfonic acid. Preferably the reaction is carried out using trifluoroacetic acid in dichloromethane as solvent.

As another example, the intermediate carboxy ester derivatives of formula (XIa) being obtained in step (g) of the above processes, can be first converted into the free carboxy acid derivative by means of hydrolysis carried out according to conventional methods, then easily supported onto a polymeric resin, for instance through the formation of a carboxamido group.

The intermediate thus supported may be subsequently reacted according to the remaining steps of the process. The above synthetic pathway can be summarized as follows:

-   wherein R2, R2′″, R^(a) and the resin are as defined above.

Therefore, it is a further object of the present invention a process for preparing the compounds of formula (I), and the pharmaceutically acceptable salts thereof, which process comprises:

-   v) hydrolyzing under acid or basic conditions the compound of     formula (XI) wherein R1 is —OR^(a) and R^(a) is C₁-C₆ alkyl; -   w) reacting the resultant acid derivative with a derivatized formyl     polystyrenic resin of formula (XIX):     (P)—CH₂—NHR^(a)  (XIX) -   wherein (P) is the resin and R^(a) is as defined above; -   z) reacting of the resultant compound of formula (XXIII):

-   wherein (P) and R^(a) are as described above, with a boronic acid or     ester of formula (XII):     R2′″B(OZ″Z′″)₂  (XII) -   wherein R2′″ is R^(d) and R^(d) is a group optionally further     substituted, selected from straight or branched C₁-C₆ alkyl, C₃-C₆     cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆     alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl or heteroaryl C₁-C₆ alkyl,     and Z″ and Z′″ are as defined above; -   x) cleaving the resin under acidic conditions from the resultant     compound of formula (XXVI):

-   to give a compound of formula (I), wherein R2′″ is as defined above     and R1 is —NHR^(a), -   wherein R^(a) is as defined above, optionally separating the     resultant compound of formula (I) into the single isomers; -   converting the resultant compound of formula (I) into a different     compound of formula (I) and/or into a pharmaceutically acceptable     salt if desired.

According to step (v) of the process, the hydrolysis of a compound of formula (XIa) is carried out as described under step (m.1) and step (p).

According to step (w) of the process, the reaction with the polystyrene resin is performed as described under step (r).

According to step (z) of the process, the reaction with the boronic acid or ester of formula (XII) wherein R2′″ is aryl or heteroaryl, is performed as described under step (h.1).

According to step (x) of the process, the cleavage of the resin is performed as described under step (u).

Clearly, by working according to combinatorial chemistry techniques as formerly indicated, a plurality of compounds of formula (I) may be obtained.

Hence, it is a further object of the present invention a library of two or more compounds of formula (I)

-   wherein -   R1 is a group —NR^(a)R^(b) or —OR^(c), -   R2 is —NH₂, —NHCOR^(c), —NHCONHR^(c), —NHSO₂R^(c), —C≡CR^(d) or     R^(d), -   wherein R^(a), R^(b), R^(c) and R^(d), the same or different, are     each independently hydrogen or a group optionally further     substituted, selected from straight or branched C₁-C₆ alkyl, C₂-C₆     alkenyl or C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl,     heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl,     heteroaryl and heteroaryl C₁-C₆ alkyl, or R^(a) and R^(b), taken     together with the nitrogen atom to which they are bonded, may form     an optionally substituted 3 to 7 membered heterocyclyl or     heteroaryl, optionally containing one additional heteroatom or     heteroatomic group selected from S, O, N or NH, and pharmaceutically     acceptable salts thereof.

According to a preferred embodiment of the invention, the aforementioned library comprises the compounds of formula (I) wherein R1 is a group —NR^(a)R^(b) and R^(a) and R^(b) are both hydrogen atoms or one of them is a hydrogen atom and the remaining one of R^(a) or R^(b) is a straight or branched C₁-C₆ alkyl or C₂-C₆ alkenyl group or it is an optionally substituted aryl or aryl C₁-C₆ alkyl group.

Also preferred is a library of compounds of formula (I) wherein R2 is a group —NHCOR^(c) with R^(c) as a straight or branched C₁-C₆ alkyl, cycloalkyl or optionally substituted aryl or arylalkyl group.

Also preferred is a library of compounds of formula (I) wherein R2 is a group

—NHCONHR^(c) with R^(c) as a hydrogen atom or as a straight or branched C₁-C₆ alkyl, optionally substituted aryl or arylalkyl group.

For a general reference to the above libraries of compounds of formula (I) see the experimental section.

From all of the above, it is clear to the skilled person that once a library of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives is thus prepared, for instance consisting of about a thousands of compounds of formula (I), the said library can be very advantageously used for screening towards given kinases, as formerly reported.

See, for a general reference to libraries of compounds and uses thereof as tools for screening biological activities, J. Med. Chem. 1999, 42, 2373-2382; and Bioorg. Med. Chem. Lett. 10 (2000), 223-226.

Pharmacology

The inhibiting activity of putative kinase inhibitors and the potency of selected compounds is determined through a method of assay based on the use of the Kinase-Glo® Luminescent Kinase Assay (commercially available from Promega corporation and described in Koresawa, M. and Okabe, T. (2004) High-throughput screening with quantitation of ATP consumption: A universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev. Technol. 2, 153-60).

The depletion of ATP as a result of kinase activity can be monitored in a highly sensitive manner through the use of Kinase-Glo® or Kinase-Glo® Plus Reagent, which uses luciferin, oxygen and ATP as substrates in a reaction that produces oxyluciferin and light.

The short forms and abbreviations used herein have the following meaning:

BSA bovine serum albumine Tris 2-Amino-2-(hydroxymethyl)-1,3-propanediol Hepes N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) DTT threo-1,4-Dimercapto-2,3-butanediol THF tetrahydrofuran MTBE methyl tertiary butyl ether DIPEA N,N-diisopropylethylamine PyBOP benzotriazol-1-yloxytris(pyrrolidino)phosphonium exafluorophosphate EDC 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide DHBT 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate TFA trifluoroacetic acid TMOF trimethyl orto formate DCE dichloroethane DCM dichloromethane DMF N,N-dimethylformammide DMA N,N-dimethylacetamide DMSO dimethylsulfoxide KDa kiloDalton mg milligram μg microgram ng nanogram L liter mL milliliter μL microliter M molar mM millimolar μM micromolar nM nanomolar

Kinase reaction conditions are target (enzyme) dependent and thus undergo individual adaptations. The Kinase-Glo® Luminescent Kinase Assay can be used with virtually any kinase and substrate combination.

Also the buffer conditions may vary depending on the kinase of interest (e.g. for PKA a composition of 40 mM Tris pH 7.5, 20 mM MgC2, 0.1 mg/ml BSA, in 50 final volume is used). Typically the range of ATP titration is 0.1 μM to 10 μM.

The optimal kinase substrate results in the greatest change in luminescence when comparing kinase reaction wells with no kinase wells.

The optimal amount of kinase is determined by making two fold serial dilutions across plates using the optimal amount of ATP and optimal kinase substrate. The optimal amount of kinase to use in subsequent compound screens and IC50 determinations is the amount required for luminescence to be within the linear range of the kinase titration curve (sigmoidal dose response).

Robotized Kinase-Glo® Assay

This assay was set up for the measurement of kinase activity and/or inhibition. It is homogeneous, suitable for all type of protein kinases, quick and radioactivity-free.

We established the assay in 384 well-plates: the test mix consisted of:

-   1) 3× Enzyme mix (done in Kinase Buffer 3×), 5 μl/well -   2) 3× substrate and ATP mix (done in ddH2O), 5 μl/well -   3) 3× compound of formula (I) (diluted into ddH2O—3% DMSO)—5     μl/well)

As an outcome, the percentage of inhibition at 10 μM was evaluated for each compound tested: see below for compound dilution and assay scheme. Each enzyme had its own buffer constitution, substrate type and concentration. Incubation time instead was 90 min for all targets.

Test compounds were received as a 1 mM solution in 100% DMSO into 96 well plates. The plates were diluted to 30 M in ddH2O, 3% DMSO; 4 plates are reorganized in 384 well plate by dispensing 5 μl of each 96 wp into quadrants of a 384 wp. In well P23 and P24 the internal standard inhibitor staurosporine was added.

Assay Scheme

Test plates were first added with 5 μl of the compound dilution (30 μM, corresponding to 3× dilution) and then loaded onto a robotized station together with one reservoir for the Enzyme mix (3×) and one for the ATP mix (3×), specific for each target under study.

To start the assay, the robot aspirated 5 μl of ATP/Substrate mix, made an air gap inside the tips (5 μl) and aspirated 5 μl of Enzyme mix. The subsequent dispensation into the test plates allowed the kinase reaction to start after 3 cycles of mixing, done by the robot itself by up and down pipetting. At this point, the correct concentration was restored for all reagents.

The robot incubated the plates for 90 minutes at room temperature, and then stopped the reaction by pipetting 15 μl of Kinase-Glo® reagent into the reaction mix. Three cycles of mixing were done immediately after the addition of the reagent.

The principle of the Kinase-Glo® technique is the presence in the reagent mixture of oxygen, luciferin and luciferase enzyme: in the presence of ATP, remaining from the kinase reaction, oxi-luciferin is produced with the emission of light, directly dependent on the amount of ATP. For optimal performances of this technique, the kinase reaction should utilize at least 15-20% of the available ATP.

After another 60 minutes of incubation to stabilize the luminescent signal, the plates were read on a ViewLux® instrument. Data were analyzed using the software package Assay Explorer® that provided percent inhibition data.

As example herein are reported the assay conditions used for testing the compounds of formula (I) against ALK (the ALK protein was prepared as described in WO2009013126, the substrate ALKtide YFF APCo was obtained in batches of >95% peptide purity from American Peptide Company, Inc. (Sunnyvale, Calif., USA).

-   Assay Conditions: -   ATP concentration: 1 μM -   Enzyme concentration: 100 nM -   Substrate concentration ALKtide YFF APCo: 80 μM -   Reaction buffer: Hepes 50 mM pH 7.5, MgCl2 5 mM, MnCl2 1 mM, DTT 1     mM, NaVO₃ 3 uM, 0.2 mg/ml BSA Assay procedure: add 5 ul compound of     formula (I) (3×), add 5 μl ATP/S mix (3×) in buffer 1×; add 5 μl     enzyme in buffer 2×+3× BSA; for the blank, add 5 μl buffer2×+3× BSA     without enzyme. After 90 minutes of incubation, add 15 μl/well of     Kinase-Glo reagent. After 60-90 minutes of incubation to stabilize     the luminescent signal, the plates are read on a ViuwLux instrument.

The compounds of the present invention were found active at a concentration from 10 to 10000 nM.

Biochemical Assay for Inhibitors of PIM-1 Kinase Activity

The inhibitory activity of putative kinase inhibitors and the potency of selected compounds were determined using a trans-phosphorylation assay.

Specific peptide or protein substrates are trans-phosphorylated by their specific ser-thr or tyr kinase in the presence of ATP traced with ³³P-γ-ATP, and in the presence of their own optimal buffer and cofactors.

At the end of the phosphorylation reaction, more than 98% unlabeled ATP and radioactive ATP is captured by an excess of the ion exchange dowex resin; the resin then settles down to the bottom of the reaction plate by gravity. Supernatant is subsequently withdrawn and transferred into a counting plate, then evaluated by β-counting.

Reagents/Assay Conditions

-   i. Dowex Resin Preparation -   500 g of wet resin (SIGMA, custom prepared resin DOWEX 1×8 200-400     mesh, 2.5 Kg) are weighed out and diluted to 2 l in 150 mM sodium     formate, pH 3.00.

The resin is allowed to settle down (some hours) and then the supernatant is discarded.

After three washes as above over a couple of days, the resin is allowed to settle and two volumes (wrt the resin volume) of 150 mM sodium formate buffer are added.

The pH is then measured and should be around 3.00

The washed resin is stable for more than one week; the stock resin is kept at 4° C. before use.

-   ii. Kinase Buffer (KB)

The buffer for PIM-1 assay was composed of HEPES 50 mM, at pH 7.5, with 10 mM MgCl₂, 1 mM DTT, 3 μM NaVO₃, and 0.2 mg/ml BSA

Full-length human PIM-1 was expressed and purified as described in Bullock A N, et Al J. Biol. Chem. 2005, 280, 41675-82.

The enzyme showed a linear kinetic after a step of pre-activation by auto-phosphorylation in the following conditions: 1.7 μM PIM1 was incubated 1 hour RT at 28° C. in the presence of 125 μM ATP

-   iii. Assay Conditions -   ATP concentration: 200 μM -   ³³P-μ-ATP: 6 nM -   Enzyme concentration: 1 nM -   Substrate concentration Aktide (Chemical Abstract Service Registry     Number 324029-01-8) : 25 μM

Robotized Dowex Assay

The test mix consisted of:

-   1) 3× Enzyme mix (done in Kinase Buffer 3×), 5 μL/well -   2) 3× substrate and ATP mix (done in ddH2O), together with     ³³P-γ-ATP, 5 μL /well -   3) 3× test compounds (diluted into ddH2O—3% DMSO)—5 μL/well

See below for compound dilution and assay scheme

Compound dilution and assay scheme is defined below:

-   i. Dilution of Compounds

Test compounds are received as a 1 mM solution in 100% DMSO, distributed into 96 or 384 well plates:

-   a) for percent inhibition studies (HTS), individual dilution plates     at 1 mM are diluted at a 3× concentration (30 μM) in ddH2O (3%     DMSO=final concentration) using a Beckman NX automated pipetting     platform. The same instrument is used for distributing the diluted     mother plates into the test plates. -   b) for IC50 determination (KSS platform), 100 μl of each compound at     1 mM in 100% DMSO are transferred from the original plate into the     first column of another 96 well plate (A1 to G1); well H1 is left     empty for the internal standard inhibitor, usually staurosporine.

An automated station for serial dilutions (Biomek FX, Beckman) is used for producing 1:3 dilutions in 100% DMSO, from line A1 to A10, and for all the seven compounds in the column. Moreover, 4-5 copies of daughter plates are prepared by reformatting 5 μL of this first set of 100% DMSO dilution plates into 384 deep well-plates: one copy of the daughter plates with the serial dilutions of test compounds will be thaw the day of the experiments, reconstituted at a 3× concentration with water and used in the IC50 determination assays. In a standard experiment, the highest concentration (3×) of all compounds is 30 μM, while the lowest one is 1.5 nM.

Each 384 well-plate will contain reference wells (total enzyme activity vs. no enzymatic activity) for the Z′ and signal to background evaluation.

-   ii. Assay Scheme

384-well plates, V bottom (test plates) are prepared with 5 μL of the compound dilution (3×) and then placed onto a PlateTrak 12 robotized station (Perkin Elmer; the robot has one 384-tips pipetting head for starting the assay plus one 96-tips head for dispensing the resin) together with one reservoir for the Enzyme mix (3×) and one for the ATP mix (3×).

At the start of the run, the robot aspirates 5 μL of ATP mix, makes an air gap inside the tips (2 μL) and aspirates 2 μL of PIM mix. The following dispensation into the plates allows the kinase reaction to start upon 3 cycles of mixing, done by the robot itself.

At this point, the correct concentration is restored for all reagents.

The robot incubates the plates for 60 minutes at room temperature, and then stops the reaction by pipetting 70 μL of dowex resin suspension into the reaction mix. Three cycles of mixing are done immediately after the addition of the resin.

The resin suspension is very dense; in order to avoid tip clogging, wide bore tips are used to dispense it.

Another mixing cycle is performed after all the plates are stopped, this time using normal tips: the plates are then allowed to rest for about one hour in order to maximize ATP capture. At this point, 20 μL of the supernatant are transferred into 384-Optiplates (Perkin-Elmer), with 70 μL of Microscint 40 (Perkin-Elmer); after 5 min of orbital shaking the plates are read on a Perkin-Elmer Top Count radioactivity counter.

iii. Data Analysis

Data are analysed by an internally customized version of the SW package “Assay Explorer” that provides either % inhibition for primary assays or sigmoidal fittings of the ten-dilutions curves for IC50 determination in the secondary assays/hit confirmation routines.

Biochemical Assay for Inhibitors of PIM-2 Kinase Activity

The inhibitory activity of putative kinase inhibitors and the potency of selected compounds were determined using a trans-phosphorylation assay as described above for PIM-1.

i. Kinase Buffer (KB)

The buffer for PIM-2 assay was composed of HEPES 50 mM, at pH 7.5, with 1 mM MgCl2, 1 mM DTT, 3 μM NaVO₃, and 0.2 mg/ml BSA

Full-length human PIM-2 was expressed and purified as described in Fedorov O, et al, PNAS 2007 104, 51, 20523-28).

ii. Assay Conditions

-   ATP concentration: 4 μM -   ³³P-μ-ATP: 1 nM -   Enzyme concentration: 1.5 nM -   Substrate concentration Aktide (Chemical Abstract Service Registry     Number 324029-01-8) : 5 μM

The enzyme showed a linear kinetic without the need of any step of pre-activation.

Robotized Dowex Assay

See the same procedure described for PIM-1.

The compounds of the present invention showed IC₅₀ of less 10 μM when tested against PIM-1 and PIM-2, see table A below for some examples.

In table A, the tested compounds are identified with a code that is explained below.

When the diastereoisomers are resolved, the chirality is to be intended on the 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one scaffold.

TABLE A PIM-1 IC50 PIM-2 IC50 Compound μM μM A33-M-B22 0.46 5.03 A33-M-B30 0.58 1.92 A127-M-B14 0.18 2.74 A127-M-B22 0.07 2.46 A127-M-B30 0.19 1.67 A127-M-B32 0.61 10 A127-M-B39 0.57 1.15 A127-M-B40 0.23 4.81 A127-M-B47 0.52 2.25 A128-M-B14 0.20 2.11 A128-M-B22 0.12 3.12 A128-M-B30 0.27 2.03 A128-M-B32 0.70 7.55 A128-M-B39 0.54 0.87 A128-M-B40 0.25 4.50 A129-M-B14 0.28 4.51 A129-M-B22 0.13 5.92 A129-M-B30 0.12 1.25 A132-M-B22 0.36 10 A133-M-B14 0.81 7.40 A133-M-B22 0.38 10 A133-M-B28 0.84 3.13 A133-M-B30 0.61 3.62 A134-M-B14 0.72 7.22 A134-M-B28 0.36 1.50 A134-M-B30 0.89 5.80 A137-M-B14 0.40 3.46 A137-M-B39 0.92 3.56 A139-M-B14 0.22 3.44 A139-M-B22 0.09 4.47 A139-M-B30 0.41 3.37 A139-M-B39 0.98 3.05 A139-M-B40 0.13 2.22 A140-M-B30 0.49 10 A142-M-B14 4.83 6.62 A142-M-B28 3.72 4.15 A142-M-B30 2.52 2.58 A144-M-B14 10.00 4.92 A144-M-B22 0.48 0.66 A144-M-B30 1.10 0.68 A150-M-B14 0.14 1.52 A150-M-B24 0.21 4.06 A150-M-B25 0.45 5.86 A150-M-B26 0.24 5.51 A150-M-B32 0.23 4.49 A150-M-B36 1.39 8.98 A150-M-B38 1.06 7.51 A150-M-B39 0.22 0.60 A150-M-B40 0.04 0.98 A150-M-B42 0.59 10 A150-M-B43 0.79 5.89 A150-M-B45 0.58 4.65 A150-M-B48 0.12 2.86 A150-M-B49 0.23 1.61 A150-M-B52 0.43 5.17 A151-M-B14 0.10 2.25 A151-M-B32 0.49 10 A151-M-B39 4.11 3.69 A133-M-B61 isomer R 5.94 10 A127-M-B61 isomer R 0.38 3.90 A157-M-B61 isomer R 0.27 2.83 A158-M-B61 isomer R 0.86 5.55 A133-M-B61 isomer S 0.07 4.79 A127-M-B61 isomer S 0.02 0.25 A133-M-B62 isomer R 4.83 10 A127-M-B62 isomer R 1.84 2.62 A157-M-B62 isomer R 1.14 1.05 A158-M-B62 isomer R 0.55 0.66 A133-M-B62 isomer S 0.13 1.33 A127-M-B62 isomer S 0.09 0.52 A133-M-B63 2.54 10 A127-M-B63 0.39 2.44 A157-M-B63 0.69 2.37 A158-M-B63 0.40 3.05 A133-M-B64 isomer R 2.04 10 A127-M-B64 isomer R 2.91 10 A157-M-B64 isomer R 0.70 2.81 A133-M-B64 isomer S 0.56 2.92 A127-M-B64 isomer S 0.14 0.68 A133-M-B65 isomer S 0.05 0.82 A127-M-B65 isomer S 0.01 0.18 A157-M-B65 isomer S 0.01 0.10 A157-M-B65 isomer R 0.15 0.50 A158-M-B65 isomer S 0.03 0.18

From all of the above, the novel compounds of formula (I) of the invention appear to be particularly advantageous in the therapy of diseases caused by dysregulated protein kinase activity such as cancer.

The compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within the approved dosage range.

Compounds of formula (I) may be used sequentially with known anticancer agents when a combination formulation is inappropriate.

The compounds of formula (I) of the present invention, suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and administration route.

For example, a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mg per dose, from 1 to 5 times daily. The compounds of the invention can be administered in a variety of dosage forms, e.g., orally, in the form tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form suppositories; parenterally, e.g., intramuscularly, or through intravenous and/or intrathecal and/or intraspinal injection or infusion.

The present invention also includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient, which may be a carrier or a diluent.

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a suitable pharmaceutical form. For example, the solid oral forms may contain, together with the active compound, diluents, e.g., lactose, dextrose saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g., starches, arabic gum, gelatine methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disintegrating agents, e.g., starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. These pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.

The liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions. As an example, the syrups may contain, as carrier, saccharose or saccharose with glycerine and/or mannitol and sorbitol.

The suspensions and the emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydrochloride.

The solutions for intravenous injections or infusions may contain, as a carrier, sterile water or preferably they may be in the form of sterile, aqueous, isotonic, saline solutions or they may contain propylene glycol as a carrier.

The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

With the aim of better illustrating the present invention, without posing any limitation to it, the following examples are now given.

Experimental Section

General Methods

Flash Chromatography was performed on silica gel (Merck grade 9395, 60A). The high-pressure liquid chromatography retention times (HPLC: r.t. values) were determined by:

HPLC Method 1:

A Waters Alliance LC mod. 2795 equipped with a variable UV detector mod 2487, a Chemiluminescence Nitrogen detector (CLND, Antek 8060) and a Waters ZQ2000 mass detector (ESI interface) was used in this application. The total flow was splitted and distributed to the three detectors at a fixed ratio (64:15:21 UV:MS:CLND). The liquid chromatograph was equipped with a 30×3.0 mm I.D. column (Waters xBridge C18, 3.5 um particles), thermostated at 50° C. Two mobile phases were used: phase A was 0.05% w/v formic acid (1 mL/L of 50% formic acid Fluka 09676 in highly purified water) and phase B was 70/25/5 (v/v/v) MeOH/iPrOH/H2O containing 0.035% w/v of formic acid (700 uL/L of 50% formic acid Fluka 09676).

A 5 uL volume of 1 mM nominal sample solution in DMSO was injected (sequential, partial loop mode with no air gaps) and a generic reversed phase gradient analysis (classified as method “IN63SEQ79”) was carried out at 0.8 mL/min from 0% to 100% of phase B (v/v) over 5 min, held 0.7 min at 100% B and steeply reverted to 0% B at 5.71 min, with the run stop time set at 6.3 min. The total analysis time (“between injections”) was 7.9 min.

The UV detector was operated at 220 nm, 5 Hz sampling rate. The MS device was operated at 3.2 kV capillary voltage, 30 V cone, 2 V extractor, 0.5 V RF lens, 400 L/hr desolvation flow, 100 L/hr cone flow, 100° C. source temperature, 150° C. desolvation temperature, ESI(+) full scan 120-1200 amu acquisition, at 1.7 Hz sampling rate The CLND detector was operated at 1050° C. furnace temp, 280 mL/min inlet oxygen flow, 80 mL/min inlet argon, 25 mL/min make-up argon, 30 mL/min ozone, 28 torr vacuum, 750 V PMT voltage, PMT chamber at +10° C., sensitivity high, select 5, 4 Hz sampling rate.

HPLC Method 2:

HPLC-MS analyses were performed on a Finnigan MAT mod. LCC) ion trap mass spectrometer, equipped with an ESI (Electrospray) ion source, the mass spectrometer is directly connected to a HPLC SSP4000 (Thermo

Separation) equipped with an autosampler Lc Pal (CTC Analytics) and an UV6000LP PDA detector.

HPLC Conditions:

Column: Phenomenex Gemini C18, 3 μm, 50 × 4.6 mm (default) Temperature 40° C. Mobile phase A: Acetate Buffer 5 mM pH 4.5:acetonitrile 95:5 (v:v) Mobile phase B: Acetate Buffer 5 mM pH 4.5:acetonitrile 5:95 (v:v) Time (min) % Mobile Phase A Elution gradient: 0 100 7 0 9 0 11 100 13 100 Flow rate:  1 mL/min Injection volume: 10 μL Column 40° C. temperature:

MS conditions:The LCQ mass spectrometer operates with an electrospray ionization (ESI) interface in positive and negative ion mode following the operation parameters reported in table 1. MS/MS experiments are performed on the most intense ion of each scan automatically by Xcalibur software. A 45% collision energy was used for the fragmentation of the precursor ions.

TABLE 1 Mass Spectrometer Instrument parameters Parameter Value Capillary Temperature (° C.) 255 Source Voltage (kV) 4.00 Capillary Voltage (V) 21.0 Tube Lens Offset (V) −5.0 Multipole RF Amplifier (Vp-p) 400.0 Multipole 1 Offset (V) −3.00 Multipole 2 Offset (V) −6.50 InterMultipole Lens Voltage (V) −16.00 Trap DC Offset Voltage (V) −10.00 Full Micro scans 3 Full AGC Target Ions 5 * 10⁷ Full Max Ion Time (ms) 150 MSn Micro scans 3 MSn AGC Target Ions 2 * 10⁷ MSn Max Ion Time (ms) 200 Electron Multiplier (V) −950.0

HPLC Method 3:

HPLC-MS analyses were performed on a Finnigan MAT mod. LCQ ion trap mass spectrometer, equipped with an ESI (Electrospray) ion source, the mass spectrometer is directly connected to a HPLC SSP4000 (Thermo Separation) equipped with an autosampler Lc Pal (CTC Analytics) and an UV6000LP PDA detector.

HPLC conditions:

Column: Phenomenex Gemini C18, 3 μm, 50 × 4.6 mm (default) Temperature 40° C. Mobile phase A: Acetate Buffer 5 mM pH 4.5:acetonitrile 95:5 (v:v) Mobile phase B: Acetate Buffer 5 mM pH 4.5:acetonitrile 5:95 (v:v) Time (min) % Mobile Phase A Elution gradient: 0 100 2 80 9 60 10 0 12 0 12.10 100 Flow rate:  1 mL/min Injection volume: 10 μL Column 40° C. temperature:

MS Conditions:

The LCQ mass spectrometer operates with an electrospray ionization (ESI) interface in positive and negative ion mode following the operation parameters reported in table 2. MS/MS experiments are performed on the most intense ion of each scan automatically by Xcalibur software. A 45% collision energy was used for the fragmentation of the precursor ions.

TABLE 2 Mass Spectrometer Instrument parameters Parameter Value Capillary Temperature (° C.) 255 Source Voltage (kV) 4.00 Capillary Voltage (V) 21.0 Tube Lens Offset (V) −5.0 Multipole RF Amplifier (Vp-p) 400.0 Multipole 1 Offset (V) −3.00 Multipole 2 Offset (V) −6.50 InterMultipole Lens Voltage (V) −16.00 Trap DC Offset Voltage (V) −10.00 Full Micro scans 3 Full AGC Target Ions 5 * 10⁷ Full Max Ion Time (ms) 150 MSn Micro scans 3 MSn AGC Target Ions 2 * 10⁷ MSn Max Ion Time (ms) 200 Electron Multiplier (V) −950.0

HPLC Method 4:

Analyses were performed on a Waters Acquity UPLC™ System equipped with a 2996 PDA (UV-VIS), and Acquity ELSD™ detectors. The LC system was coupled to a Waters Acquity 3100 SQD™ single quadrupole mass spectrometer for atomic mass determinations. A Waters Acquity UPLC™ BEH C18, 1.7 μm, 2.1×50 mm column at 45° C. was used with a flow rate of 0.7 mL/min of the following binary solvent system and gradient.

Mobile Phase A: 0.1% Trifluoroacetic Acid in H₂0/Acetonitrile (95:5) Mobile Phase B: Acetonitrile/H₂O (95:5) Time (min) % Mobile Phase A % Mobile Phase B 0.00 95% 5% 2.00 5% 95%

MS Conditions:

The LCQ mass spectrometer operates with an electrospray ionization (ESI) interface in positive and negative ion mode following the operation parameters reported in table 3. MS/MS experiments are performed on the most intense ion of each scan automatically by Xcalibur software. A 45% collision energy was used for the fragmentation of the precursor ions.

TABLE 3 Mass Spectrometer Instrument parameters Ionization Mode ESI+ and ESI− Capillary Voltage 3 kV (ES+); 3 kV (ES−) Cone Voltage 30 V (ES+); 30 V (ES−) Extractor Voltage  1 V RF Lens Voltage  0.1 V Source Temperature 120° C. Desolvation Temperature 350° C. Cone Gas Flow 100 L/Hr Desolvation Gas Flow 600 L/Hr LM Resolution 15.0 HM Resolution 15.0 Ion Energy  0.3 Gain  1 Scan Mode Full Scan (Range = 100-800 m/z) ScanTime = 0.1 s Inter-Scan Delay = 0.02 s

HPLC Method 5:

Analyses were performed on a Waters Alliance HT 2795 System equipped with a 996 PDA (UV-VIS) detector. The LC system was coupled to a Waters/Micromass ZQ™ single quadrupole mass spectrometer for atomic mass determinations. A Waters Ascentis Express C18, 2.7 μm, 4.6×50 mm column was used with a flow rate of 1.0 mL/min of the following binary solvent system and gradient.

Mobile Phase A: 0.1% Trifluoroacetic Acid in H₂0/Acetonitrile (95:5) Mobile Phase B: Acetonitrile/H₂O (95:5) Time (min) % Mobile Phase A % Mobile Phase B 0.00 90% 10% 4.00 10% 90% 4.10 0% 100%

MS Conditions:

The LCQ mass spectrometer operates with an electrospray ionization (ESI) interface in positive and negative ion mode following the operation parameters reported in table 4. MS/MS experiments are performed on the most intense ion of each scan automatically by Xcalibur software. A 45% collision energy was used for the fragmentation of the precursor ions.

TABLE 4 Mass Spectrometer Instrument parameters Ionization Mode ESI+ and ESI− Capillary Voltage 3.48 kV (ES+); 2.76 kV (ES−) Cone Voltage 15 V (ES+); 27 V (ES−) Extractor Voltage  1 V RF Lens Voltage  0.1 V Source Temperature 120° C. Desolvation Temperature 240° C. Cone Gas Flow 100 L/Hr Desolvation Gas Flow 600 L/Hr LM Resolution  15.0 HM Resolution  15.0 Ion Energy  0.5 Multiplier 600 Scan Mode Full Scan (Range = 100-800 m/z) ScanTime = 0.5 s; Inter-Scan Delay = 0.3 s

Retention times (HPLC r.t.) are given in minutes at 220 nm or at 254 nm. Mass is given as m/z ratio.

When necessary, the compounds were purified by preparative HPLC using one of the following two systems. A Waters X-Bridge Prep Shield RP18 (19×100 mm, 5 μm) column or a Phenomenex Gemini C18 (21.2×250 mm, 10 μm) column, using a Waters FractionLynx Autopurification System equipped with a 996 Waters PDA detector and a Micromass mod. ZQ single quadrupole mass spectrometer, electron spray ionization, positive mode. Mobile phase A was water 0.05% NH₃/acetonitrile 95:5, and Mobile phase B was acetonitrile. Gradient from 10 to 90% B in 8 min or 15 min. Flow rate 20 ml/min.

Alternatively, purifications were performed on a Biotage Paraflex Flex System, equipped with four independent, binary flow-stream pumps, a UV detector with four-channel flow cell monitoring two wavelengths (220 and 254 nm), and four fraction collectors. Fractionation was performed at 254 nm. Waters XTerra Prep RP18, 5 μm, 100×19 mm columns were used at a flow rate of 20 mL/min. Gradients were applied according to the retention time of the desired product obtained from the analytical HPLC analysis.

Standard Binary Solvent System:

-   Mobile Phase A: 0.1% Trifluoracetic Acid in H₂O/Acetonitrile (95:5) -   Mobile Phase B: Acetonitrile -   Gradient A:

Time (min) % Mobile Phase A % Mobile Phase B 0.0 100% 0% 6.0 80% 20% 8.0 80% 50% 8.5 50% 100%

-   Gradient B:

Time (min) % Mobile Phase A % Mobile Phase B 0.0 100% 0% 6.0 70% 30% 8.0 0% 100%

-   Gradient C:

Time (min) % Mobile Phase A % Mobile Phase B 0.0 100% 0% 6.0 50% 50% 8.0 0% 100%

-   Gradient D:

Time (min) % Mobile Phase A % Mobile Phase B 0.0 90% 10% 6.0 30% 70% 8.0 0% 100%

¹H-NMR spectrometry was performed on a Bruker AVANCE 400 MHz single bay instrument with gradients. It is equipped with a QNP probe (interchangeable 4 nuclei probe—¹H, 13C, 19F and 31P) (NMR method 1) or on a Mercury VX 400 operating at 400.45 MHz equipped with a 5 mm double resonance probe [1H (15N-31P) ID_PFG Varian] (NMR method 2).

The compounds of formula (I), having an asymmetric carbon atom and obtained as racemic mixture, were resolved by HPLC separation on chiral columns. In particular, for example, preparative columns CHIRALPACK® AD, CHIRALPACK® AS, CHIRALCELL® OJ can be used.

Alternatively, when R1 contains a chiral center and gives rise to a pair of diastereomers, traditional reversed phase HPLC techniques described above were utilized to resolve the species.

Some compounds prepared according to solution and combinatorial chemistry techniques have been conveniently and unambiguously identified, as per the coding system of tables III together with HPLC retention time (methods 1-5) and mass.

Each code, which identifies a single specific compound of formula (I), consists of three units A-M-B.

A represents any substituent R2—[see formula (I)] and is attached in position 7 of the 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one moiety; each A substituent is represented in the following table I.

B represents any substituent R1—[see formula (I)] and is attached to the rest of the 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one moiety through the carbon atom of the carbonyl group so as to get 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives; each B substituent is represented in the following table II.

M refers to the central core of the divalent 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one moiety being substituted in position 7 by groups A and at the carbonyl group by groups B, substantially as follows:

For ease of reference, each A and B group, in tables I and II respectively, have been identified with the proper chemical formula and an indication of the attachment point with the molecule core M.

To illustrate, compound A3-M-B5 of table III (entry 13) represents the core M, 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one, being substituted at 7-position by the group A3 and by the group B5 through the carbonyl group; likewise, compound A24-M-B8 of table III (entry 137) represents the core M, 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one, being substituted at 7-position by the group A24 and by the group B8 through the carbonyl group, as follows:

TABLE I A groups Fragment CODE

A1

A2

A3

A4

A5

A6

A7

A8

A9

A10

A11

A12

A13

A14

A15

A16

A17

A18

A19

A20

A21

A22

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A45

A46

A47

A48

A49

A50

A51

A52

A53

A54

A55

A56

A57

A58

A59

A60

A61

A62

A63

A64

A65

A66

A67

A68

A69

A70

A71

A72

A73

A74

A75

A76

A77

A78

A79

A80

A81

A82

A83

A84

A85

A86

A87

A88

A89

A90

A91

A92

A93

A94

A95

A96

A97

A98

A99

A100

A101

A102

A103

A104

A105

A106

A107

A108

A109

A110

A111

A112

A113

A114

A115

A116

A117

A118

A119

A120

A121

A122

A123

A124

A125

A126

A127

A128

A129

A130

A131

A132

A133

A134

A135

A136

A137

A138

A139

A140

A141

A142

A143

A144

A145

A146

A147

A148

A149

A150

A151

A152

A153

A154

A155

A156

A157

A158

TABLE II B groups Fragment CODE

B1

B2

B3

B4

B5

B6

B7

B8

B9

B10

B11

B12

B13

B14

B15

B16

B17

B18

B19

B20

B21

B22

B23

B24

B25

B26

B27

B28

B29

B30

B31

B32

B33

B34

B35

B36

B37

B38

B39

B40

B41

B42

B43

B44

B45

B46

B47

B48

B49

B50

B51

B52

B53

B54

B55

B56

B57

B58

B59

B60

B61

B62

B63

B64

B65

Preparation of 2,2,2-trichloro-1-(4-nitro-1H-pyrrol-2-yl)ethanone (III):

Nitric acid (90%, 2 mL) was added dropwise over a period of 30 minutes to a solution of 2,2,2-trichloro-1-(1H-pyrrol-2-yl) ethanone (II) (1 g, 4.7 mmol) in acetic anhydride (10 ml), cooled to −40° C. The reaction mixture was allowed to warm up slowly to room temperature and stirred for 6 h. The solvent was evaporated under vacuum and the residue purified by flash chromatography (hexane-EtOAc 9:1) to obtain the compound of formula (III) as a yellow solid (670 mg, 55% yield). 2,2,2-Trichloro-1-(5-nitro-1H-pyrrol-2-yl)ethanone was also obtained as side product (349 mg, 29% yield).

LCMS (HPLC Method 2): m/z 256 [M−H]⁻@r.t. 5.44 min. ¹H NMR (400 MHz, DMSO-d₆) δ=13.65 (br. s., 1 H), 8.39 (dd, J=1.4, 3.6 Hz, 1 H), 7.73 (t, J=1.8 Hz, 1 H)

Preparation of ethyl(7-nitro-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (V, where R1=OCH₂CH₃):

Ethyl (2E)-4-aminobut-2-enoate trifluoroacetate (IV) (5.99 g, 24.6 mmol) was added to a solution of 2,2,2-trichloro-1-(4-nitro-1H-pyrrol-2-yl)ethanone (III) (3.17 g, 12.3 mmol) and DIPEA (12.6 mL, 73.8 mmol) in dry CH₂Cl₂ (120 mL) and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated under vacuum and the residue purified by flash chromatography (hexane-EtOAc 2:3), to obtain the compound of formula (V) (where R1=OCH₂CH₃) as a light-yellow solid (3.19 g, 97% yield).

LCMS (HPLC Method 2): m/z 268 [M+H]⁺@r.t. 3.48 min. ¹H NMR (400 MHz, DMSO-d₆)) δ=8.13 (br. s., 1 H), 8.12 (d, J=1.7 Hz, 1 H), 7.14 (d, J=1.8 Hz, 1 H), 4.74-4.84 (m, 1 H), 4.11 (q, J=7.2 Hz, 2 H), 3.75 (ddd, J=1.8, 4.2, 13.4 Hz, 1 H), 3.44 (dt, J=4.2, 13.4 Hz, 1 H), 2.96 (dd, J=1.6, 6.8 Hz, 2 H), 1.19 (t, J=7.1 Hz, 3 H)

EXAMPLE 1 Preparation of ethyl(7-amino-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate hydrochloride (I)

To a solution of ethyl(7-nitro-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (V, where R1=OCH₂CH₃) (0.55 g, 2.1 mmol) in ethanol 100% (20 mL) was added hydrochloric acid (4 M solution in 1,4-dioxane, 0.52 mL, 2.1 mmol). The reaction mixture was stirred at room temperature in the presence of Pd-C (10%) (0.11 g), under hydrogen atmosphere (50 psi). After 7 h the solid was filtered through celite (washed with ethanol) and the solvent evaporated under vacuum, to obtain compound ethyl(7-amino-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate hydrochloride (I) as a light-brown solid (0.56 g, 98% yield), used without further purification in the next steps. Very hygroscopic product. To be stored for a short time and under inert gas atmosphere.

LCMS (HPLC Method 2): m/z 238 [M−H]⁻@r.t. 1.89 min (broad peak). ¹ H NMR (400 MHz, DMSO-d₆) δ=9.75 (br. s., 2 H), 7.84 (br. s., 1 H), 7.10 (d, J=1.8 Hz, 1 H), 6.62 (d, J=1.8 Hz, 1 H), 4.64-4.75 (m, 1 H), 4.05-4.15 (m, 2 H), 3.64-3.75 (m, 1 H), 3.34-3.44 (m, 1 H), 2.83-2.94 (m, 1 H), 2.73-2.82 (m, 1 H), 1.20 (t, J=7.1 Hz, 3 H).

EXAMPLE 2 Preparation A7-M-B1 (entry 34, table III)

A solution of 4-fluorobenzoic acid (0.29 g, 2.1 mmol), 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC) (0.4 g, 2.1 mmol), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (DHBT) (0.34 g, 2.1 mmol) and N,N-diisopropylethylamine (DIPEA) (0.75 mL, 4.2 mmol) in dry acetonitrile (10 mL) was stirred at room temperature for 10 min, before adding ethyl(7-amino-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate hydrochloride (I) (0.52 g, 1.9 mmol). The reaction mixture was stirred overnight at the same temperature. The solvent was evaporated under vacuum and the residue purified by flash chromatography (EtOAc+5% MeOH), to obtain compound A7-M-B1 (entry 34, table III) as an off-white solid (0.49 g, 71% yield).

LCMS (HPLC Method 2): m/z 361 [M+H]⁺@r.t. 3.99 min. ¹H NMR (500 MHz, DMSO-d₆) δ=10.37 (s, 1 H), 7.97-8.02 (m, 2 H), 7.66 (br. s., 1 H), 7.44 (d, J=1.6 Hz, 1 H), 7.31-7.38 (m, 2 H), 6.73 (d, J=1.6 Hz, 1 H), 4.63 (ddd, J=3.2, 3.3, 6.8 Hz, 1 H), 4.09 (q, J=7.0 Hz, 2 H), 3.66-3.72 (m, 1 H), 3.34-3.39 (m, 1 H), 2.81-2.89 (m, 1 H), 2.68-2.77 (m, 1 H), 1.19 (t, J=7.1 Hz, 3 H).

EXAMPLE 3 Preparation A9-M-B1 (entry 54, table III)

N,N-diisopropylethylamine (DIPEA) (0.19 mL, 1.1 mmol) was added to a solution of 1-fluoro-4-isocyanatobenzene (0.15 mL, 1.2 mmol) and (a suspension of) ethyl(7-amino-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate hydrochloride (I) (0.30 g, 1.1 mmol) in dry dichloromethane (10 mL). The reaction mixture was stirred at room temperature overnight, the solvent was evaporated under vacuum and the residue purified by flash chromatography (EtOAc+5% MeOH), to obtain compound A9-M-B1 (entry 54, table III) as an off-white solid (0.33 g, 80% yield).

LCMS (HPLC Method 2): m/z 376 [M+H]⁺@r.t. 4.04 min. ¹H NMR (500 MHz, DMSO-d₆) δ=8.56 (s, 1 H), 8.37 (s, 1H), 7.59 (d, J=2.6 Hz, 1 H), 7.38-7.46 (m, 2 H), 7.10-7.11 (m, 1 H), 7.05-7.12 (m, 2 H), 6.48 (d, J=1.8 Hz, 1 H), 4.53-4.59 (m, 1 H), 4.06-4.12 (m, 2 H), 3.64-3.70 (m, 1 H), 3.29-3.36 (m, 1 H), 2.79-2.85 (m, 1 H), 2.69-2.74 (m, 1 H), 1.19 (t, J=7.1 Hz, 3 H).

EXAMPLE 4 Preparation A8-M-B1 (entry 52, table III)

N-methylmorpholine (0.28 mL, 2.6 mmol) was added to a solution of 4-fluorobenzenesulfonyl chloride (0.25 g, 1.3 mmol) and (a suspension of) ethyl(7-amino-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate hydrochloride (I) (0.32 g, 1.2 mmol) in dry dichloromethane (10 mL) and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated under vacuum and the residue purified by flash chromatography (EtOAc), to obtain compound A8-M-B1 (entry 52, table III) as an off-white solid (0.30 g, 64% yield).

LCMS (HPLC Method 2): m/z 397 [M+H]⁺@r.t. 3.96 min. ¹H NMR (500 MHz, DMSO-d₆) δ=9.75 (s, 1 H), 7.70-7.77 (m, 2 H), 7.65 (d, J=2.9 Hz, 1 H), 7.35-7.42 (m, 2 H), 6.67 (d, J=1.8 Hz, 1 H), 6.20 (d, J=1.8 Hz, 1 H), 4.50-4.56 (m, 1 H), 3.99-4.10 (m, J=3.5, 3.7, 7.1, 7.1, 10.6 Hz, 2 H), 3.58-3.64 (m, 1 H), 3.26-3.32 (m, 1 H), 2.78 (dd, J=6.4, 16.0 Hz, 1 H), 2.58-2.68 (m, 1 H), 1.16 (t, J=7.1 Hz, 3 H).

Preparation of 2,2,2-trichloro-1-(4-iodo-1H-pyrrol-2-yl)ethanone (IX)

Iodine (1.2 g, 4.7 mmol) was added portion wise to a solution of 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethanone (1 g, 4.7 mmol) and silver trifluoroacetate (1.1 g, 5 mmol) in dry dichloromethane (24 mL), cooled to 0° C. The reaction mixture was allowed to warm up slowly to 18° C. (water bath) and stirred at the same temperature for 5 h. The solid was filtered, the organic phase washed with Na₂S₂O₅ (5% aq. solution) until decoloration occurs and finally washed with H₂O (1×20 mL). The organic phase was dried over Na₂SO₄ and filtered through a plough of SiO₂ (hexane-EtOAc 4:1), to obtain compound 2,2,2-trichloro-1-(4-iodo-1H-pyrrol-2-yl)ethanone (IX) as an off-white solid (1.49 g, 94% yield).

LCMS (HPLC Method 2): m/z 336 [M−H]⁻@r.t. 6.3 min. ¹H NMR (400 MHz, DMSO-d₆) δ=12.76 (br. s., 1 H), 7.52 (dd, J=1.3, 3.3 Hz, 1 H), 7.39 (dd, J=1.3, 2.6 Hz, 1 H).

Preparation of ethyl (2E)-4-{[(4-iodo-1H-pyrrol-2-yl)carbonyl]amino}but-2-enoate (X, where R1=OCH₂CH₃):

Ethyl (2E)-4-aminobut-2-enoate trifluoroacetate (IV) (0.97 g, 4 mmol) was added to a solution of 2,2,2-trichloro-1-(4-iodo-1H-pyrrol-2-yl)ethanone (IX) (0.68 g, 2 mmol) and N,N-diisopropylethylamine (DIPEA) (2.7 mL, 16 mmol) in dichloromethane (20 mL) and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated under vacuum and the residue purified by flash chromatography (SiO₂, hexane-EtOAc 1:1) to obtain compound ethyl (2E)-4-{[(4-iodo-1H-pyrrol-2-yl)carbonyl]amino}but-2-enoate (X, where R1=OCH₂CH₃) as an off-white solid (0.48 g, 68% yield).

LCMS (HPLC Method 2): m/z 349 [M+H]⁺@r.t. 4.7 min. ¹H NMR (400 MHz, DMSO-d₆) δ=11.82 (br. s., 1 H), 8.39 (t, J=5.8 Hz, 1 H), 7.01 (dd, J=1.5, 2.9 Hz, 1 H), 6.96 (dd, J=1.5, 2.5 Hz, 1 H), 6.90 (dt, J=4.7, 15.7 Hz, 1 H), 5.87 (dt, J=1.8, 15.7 Hz, 1 H), 4.12 (q, J=7.1 Hz, 2 H), 3.99-4.06 (m, 2 H), 1.21 (t, J=7.1 Hz, 3 H).

Preparation of ethyl(7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (XI, where R1=OCH₂CH₃)

Diaza(1,3)bicyclo[5.4.0]undecane (DBU) (0.04 mL, 0.3 mmol) was added to a solution of ethyl (2E)-4-{[(4-iodo-1H-pyrrol-2-yl)carbonyl]amino}but-2-enoate (X, where R1=OCH₂CH₃) (0.45 g, 1.3 mmol) in acetonitrile (8 mL) and the reaction mixture was stirred at room temperature for 30 min. The solvent was evaporated under vacuum and the residue purified by flash chromatography (SiO₂, hexane-EtOAc 1:1) to obtain compound ethyl (7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (XII, where R1=OCH₂CH₃) as an off-white solid (0.35 g, 79% yield).

LCMS (HPLC Method 2): m/z 349 [M+H]⁺@r.t. 4.15 min. ¹H NMR (400 MHz, DMSO-d₆) δ=7.72 (br. s., 1 H), 7.13 (d, J=1.7 Hz, 1 H), 6.72 (d, J=1.6 Hz, 1 H), 4.59-4.71 (m, 1 H), 4.10 (qd, J=1.8, 7.1 Hz, 2 H), 3.66 (ddd, J=1.7, 4.2, 13.1 Hz, 1 H), 3.30-3.38 (m, 1 H), 2.83 (d, J=6.7 Hz, 2 H), 1.19 (t, J=7.1 Hz, 3 H).

EXAMPLE 5 Preparation A21-M-B1 (entry 127, table III):

A mixture of ethyl (7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (XI, where R1=OCH₂CH₃) (50 mg, 0.14 mmol), 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride, complex with dichloromethane (1:1) (12 mg, 0.015 mmol) and 4-nitrophenylboronic acid (47 mg, 0.28 mmol) in dimethoxyethane (DME) (1 mL) was degassed before addition of sodium carbonate (45 mg, 0.42 mmol in 0.5 mL of H₂O) and the reaction mixture was stirred at 80° C. for 3 h, under an argon atmosphere. The reaction mixture was filtered through silica (washed with EtOAc) and the solvent evaporated under vacuum. The residue was purified by flash chromatography (EtOAc-hex), to obtain compound A21-M-B1 (entry 127, table III) (29 mg, 60% yield).

LCMS (HPLC Method 2): m/z 345 [M+H]⁺@r.t. 4.61 min. ¹H NMR (400 MHz, DMSO-d₆) δ=8.19 (d, J=9.0 Hz, 2H), 7.87 (d, J=9.0 Hz, 2 H), 7.80 (d, J=1.7 Hz, 1 H), 7.76 (d, J=1.8 Hz, 1 H), 7.24 (d, J=1.8 Hz, 1 H), 4.71 (ddd, J=3.4, 3.6, 6.6 Hz, 1 H), 4.04-4.17 (m, 2 H), 3.74 (ddd, J=1.8, 4.1, 13.3 Hz, 1 H), 3.35-3.45 (m, 1 H), 2.88-2.99 (m, 2 H), 1.15-1.22 (m, 3 H).

EXAMPLE 6 Preparation A22-M-B1 (entry 128, table III)

A mixture of ethyl (7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (XI, where R1=OCH₂CH₃) (50 mg, 0.14 mmol), 1,1-bis(diphenylphosphino)ferrocenepalladium(II) dichloride, complex with dichloromethane (1:1) (12 mg, 0.015 mmol) and trans-2-(4-methoxyphenyl)vinylboronic acid (50 mg, 0.28 mmol) in dimethoxyethane (DME) (1 mL) was degassed before addition of sodium carbonate (45 mg, 0.42 mmol in 0.5 mL of H20) and the reaction mixture was stirred at 80° C. for 6 h, under an argon atmosphere. The reaction mixture was filtered through silica (washed with EtOAc) and the solvent evaporated under vacuum. The residue was purified by flash chromatography (EtOAc-Hex), to obtain compound A22-M-B1 (entry 128, table III) (31 mg, 62% yield).

LCMS (HPLC Method 2): m/z 356 [M+H]⁺@r.t. 5.12 min. ¹H NMR (400 MHz, DMSO-d₆) δ=7.66 (d, J=3.2 Hz, 1H), 7.38-7.45 (m, 2 H), 7.13 (d, J=1.6 Hz, 1 H), 6.87-6.93 (m, 4 H), 6.79-6.85 (m, 1 H), 4.58-4.66 (m, 1 H), 4.12 (q, J=7.1 Hz, 2 H), 3.76 (s, 3 H), 3.65-3.73 (m, 1 H), 3.32-3.39 (m, 1 H), 2.76-2.91 (m, 2 H), 1.20 (t, J=7.1 Hz, 3 H).

EXAMPLE 7 Preparation A27-M-B1 (entry 151, table III)

A mixture of ethyl (7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (XI, where R1=OCH₂CH₃) (500 mg, 1.44 mmol), bis(triphenylphosphine)palladium(II) dichloride (50 mg, 0.07 mmol), copper(I) iodide (41 mg, 0.22 mmol), 1-chloro-4-ethynylbenzene (0.29 g, 2.15 mmol) and triethylamine (0.58 mL, 5.74 mmol) in dry dimethylformamide (14 mL) was degassed and the reaction mixture was stirred at room temperature overnight, under an argon atmosphere. The solvent was evaporated under vacuum and the residue purified by flash chromatography (EtOAc-CH₂Cl₂), to obtain compound A27-M-B1 (entry 151, table III) (0.51 g, 99% yield).

LCMS (HPLC Method 2): m/z 358 [M+H]⁺@r.t. 6.48 min. ¹H NMR (400 MHz, DMSO-d₆) δ=7.82 (br. s., 1 H), 7.42-7.50 (m, 4 H), 7.37 (d, J=1.6 Hz, 1 H), 6.78 (d, J=1.6 Hz, 1 H), 4.63-4.70 (m, 1 H), 4.11 (q, J=7.1 Hz, 2 H), 3.65-3.74 (m, 1 H), 3.33-3.41 (m, 1 H), 2.81-2.91 (m, 2 H), 1.19 (t, J=7.1 Hz, 3 H).

Preparation of ethyl (2E)-4-(diformylamino)but-2-enoate (XV)

A solution of ethyl-4-bromo-crotonate (1 g, 5.18 mmol), diformylimide sodium salt (0.59 g, 6.22 mmol) and sodium iodide (0.78 g, 5.18 mmol) in dry acetonitrile (25 mL) was stirred under reflux overnight. The solvent was evaporated under vacuum and the residue partitioned between dichloromethane and water (1:1, 40 mL). The aqueous phase was back-extracted with dichloromethane (3×15 mL) and the combined organic layers were dried over Na₂SO₄. The solvent was evaporated under vacuum and the residue purified by flash chromatography (hexane-EtOAc 6:4) to obtain compound ethyl (2E)-4-(diformylamino)but-2-enoate (XV) as a light-brown solid (0.92 g, 96% yield). In alternative, Et₂O was added to the deep brown oil residue to obtain the product as a crystalline solid.

LCMS (HPLC Method 2): m/z 186 [M−H]⁻@r.t. 3.36 min. ¹H NMR (400 MHz, DMSO-d₆) δ=9.01 (s, 2 H), 6.78 (dt, J=4.6, 15.9 Hz, 1 H), 5.88 (dt, J=2.0, 15.8 Hz, 1 H), 4.26 (dd, J=2.0, 4.5 Hz, 2 H), 4.12 (q, J=7.1 Hz, 2 H), 1.21 (t, J=7.1 Hz, 3 H)

Preparation of ethyl (2E)-4-aminobut-2-enoate trifluoroacetate (IV)

A solution of ethyl (2E)-4-(diformylamino)but-2-enoate (XV) (0.89 mg, 4.8 mmol) in a mixture trifluoroacetic acid-ethanol (absolute) (2:1, 10 mL) was stirred under reflux overnight (the reaction was followed by LC-MS and stopped when complete conversion was achieved). The solvent was evaporated under vacuum to obtain compound ethyl (2E)-4-aminobut-2-enoate trifluoroacetate (IV) as brown oil (undetermined yield), which was used without further purification in the next step.

EXAMPLE 8 Preparation A2-M-B2 (entry 8, table III)

To a solution of derivative A2-M-B1 (entry 7, table III) (24 mg, 0.07 mmol) in a mixture tetrahydrofuran-water (1:1, 2 mL) was added lithium hydroxide (6 mg, 0.04 mmol) and the reaction mixture was stirred at room temperature for 3 h. The organic phase was washed with dichloromethane (2×5 mL). The aqueous phase was acidified with hydrochloric acid (1 M) until pH<1 and extracted with EtOAc (4×10 mL). The combined organic layers were dried over Na₂SO₄ and the solvent was evaporated under vacuum to obtain compound A2-M-B2 (entry 8, table III) as an off-white solid (21 mg, 100% yield).

LCMS (HPLC Method 2): m/z 302 [M+H]⁺@r.t. 3.06 min. ¹H NMR (400 MHz, DMSO-d₆) δ=7.64 (br. s., 1 H), 7.45-7.50 (m, 2 H), 7.37 (d, J=1.8 Hz, 1 H), 6.96 (d, J=1.8 Hz, 1 H), 6.88-6.94 (m, 2 H), 4.57-4.63 (m, 1 H), 3.76 (s, 3H), 3.67-3.73 (m, 1 H), 3.37-3.42 (m, 1 H), 2.74-2.86 (m, 2 H).

EXAMPLE 9 Preparation A5-M-B5 (entry 29, table III)

To a solution of derivative A5-M-B2 (entry 23, table III) (45 mg, 0.14 mmol) in a dry mixture acetonitrile-dimethylformamide (3:1, 4 mL), 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC) (32 mg, 0.17 mmol), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (DHBT) (28 mg, 0.17 mmol) and N,N-diisopropylethylamine (DIPEA) (0.024 mL, 0.14 mmol) were added and the reaction mixture was stirred at room temperature for 10 min before adding piperidine (0.028 mL, 0.28 mmol). The reaction mixture was stirred at the same temperature overnight. The reaction mixture was then diluted with water and extracted with EtOAc (4×5 mL). The combined organic layers were dried over Na₂SO₄, the solvent evaporated under vacuum and the residue purified by prep-HPLC to obtain compound A5-M-B5 (entry 29, table III) as a white solid (13 mg, 23% yield).

LCMS (HPLC Method 2): m/z 397 [M+H]⁺@r.t. 3.74 min. ¹H NMR (400 MHz, DMSO-d₆) δ=8.50 (s, 1 H), 8.34 (s, 1H), 7.51 (d, J=2.9 Hz, 1 H), 7.42 (d, J=7.6 Hz, 2 H), 7.24 (t, J=8.0 Hz, 2 H), 7.12 (d, J=1.7 Hz, 1 H), 6.92 (t, J=7.3 Hz, 1 H), 6.48 (d, J=1.7 Hz, 1 H), 4.58 (tt, J=3.9, 6.7 Hz, 1 H), 3.67 (ddd, J=1.1, 4.3, 12.9 Hz, 1 H), 2.79 (dd, J=5.7, 16.1 Hz, 1 H), 2.74 (dd, J=7.1, 16.1 Hz, 1 H), 1.55 (quin, J=5.6 Hz, 2 H), 1.37-1.48 (m, 4 H).

Preparation of 7-nitro-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-carboxylic acid (V, where R1=OH)

LiOH.H₂O (27 mg, 1.12 mmol) was added to a solution of ethyl(7-nitro-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (V, where R1=OCH₂CH₃) (0.15 g, 0.56 mmol) in a mixture tetrahydrofuran-water (1:1, 9 mL) and the reaction mixture was stirred at room temperature for 3 h. The organic phase was washed with dichloromethane (2×10 mL). The aqueous phase was acidified with hydrochloric acid (1 M) to reach pH<1 and extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na₂SO₄ and the solvent was evaporated under vacuum to obtain compound 7-nitro-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-carboxylic acid (V, where R1=OH) as an off-white solid (101 mg, 75% yield).

LCMS (HPLC Method 2): m/z 240 [M+H]⁺@r.t. 1.05 min. ¹H NMR (400 MHz, DMSO-d₆) δ=8.13 (d, J=1.7 Hz, 1H), 8.11 (d, J=1.7 Hz, 1 H), 7.14 (d, J=1.8 Hz, 1 H), 4.70-4.79 (m, 1 H), 3.71-3.77 (m, 1 H), 3.44 (dt, J=4.3, 13.4 Hz, 1 H), 2.80-2.96 (m, 2 H).

General procedure: loading of phenethylamine (corresponding to fragment B6 of Table I) onto Acid Sensitive Methoxy Benzaldehyde polystyrene resin (AMEBA II resin).

4-(4-formyl-3-methoxyphenoxy)butyryl aminomethyl resin (copolystyrene-1% DVB) (6.0 g, 5.88 mmol, 0.98 mmol/g, 1 eq.) was suspended in dry THF (60 ml) and phenethylamine (29.4 mmol, 5 eq.) was added. The resultant suspension was shaken at 25° C. for 2 h. Then acetic acid (1.68 ml, 29.4 mmol, 5 eq.) and NaBH(AcO)₃ (3.12 g, 14.7 mmol, 3 eq.) were added and the final suspension was shaken for 16 h at 25° C. The resin was rinsed with THF (2 cycles), MeOH (2 cycles), DCM (2 cycles), MeOH (2 cycles), DMF (2 cycles) and DCM (3 cycles) then dried in nitrogen flux.

Loading of the 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one scaffold onto the resin prepared as described above.

A solution of 7-nitro-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-carboxylic acid (V, where R1=OH) (0.24 g, 1 mmol), N,N-diisopropylethylamine (DIPEA) (0.34 ml, 2 mmol) and benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (0.52 g, 1 mmol) in dry N,N-dimethylacetamide (7.5 ml) was stirred for 30 min, then was added to resin of example 17 (0.67 mmol, 1 eq) and the final suspension was shaken for 24 h at room temperature. The resin was rinsed with a cycle of DMF, MeOH, DCM (3 times), DCM (3 times) and 1,4-dioxane (once) and dried under nitrogen flux. The resin was then used in the next step.

Reduction of the nitro group:

The resin of formula (XVIII) (0.67 mmol, 1 eq) was suspended in a 2M solution of SnCl₂.2H₂O in N,N-dimethylformamide (10 ml). The final suspension was shaken for 48 hours at room temperature. The resin was rinsed with a cycle of DMF, MeOH, DCM (3 times), DCM (3 times) and 1,4-dioxane (once) and dried under nitrogen flux. The resin was then used in the next step.

The above resin bound 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one was further reacted according to the alternative steps below so as to get carboxamido and ureido derivatives.

EXAMPLE 10 Preparation of A11-M-B6 (entry 71, table III)

A carboxylic acid of formula (VI), wherein R^(c) corresponds to the fragment A11 of table II (1.35 mmol, 15 eq.) was added to a solution of 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC) (0.26 g, 1.35 mmol, 15 eq) and 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (DHBT) (0.22 g, 1.35 mmol, 15 eq) in dried N-methylpyrrolidone (NMP) (1 ml) and the solution was stirred for 30 min, then was added to resin of example 19 (0.09 mmol, 1 eq.) and shaken overnight at room temperature in a reactor (Quest 210™ or Miniblocks™). The resin was rinsed with a cycle of DMF, MeOH, DCM (3 times), DCM (3 times) and 1,4-dioxane (once) and dried under nitrogen flux. The resin was suspended in a solution of TFA-DCM (1:1, 2 ml) and shaken for 2 h at room temperature. The solution was collected and the resin was rinsed with DCM (collected as well), and a second cycle was performed. The final washing was performed with MeOH. All the collected organic layers were dried under reduced pressure affording compound A11-M-B6 (see entry 71 of table III below).

LCMS (HPLC Method 2): m/z 399 [M+H]⁺@r.t. 2.7 min. ¹H NMR (400 MHz, DMSO-d₆) δ=10.53 (s, 1 H), 9.74 (br. s., 1 H), 8.07 (t, J=5.6 Hz, 1 H), 7.67 (d, J=3.5 Hz, 1 H), 7.12-7.32 (m, 6 H), 6.60 (d, J=1.7 Hz, 1 H), 4.48-4.67 (m, 1 H), 3.94-4.09 (m, 2 H), 3.66 (dd, J=4.6, 13.3 Hz, 1 H), 2.81 (s, 6 H), 2.63-2.75 (m, 2 H).

EXAMPLE 11 Preparation of A17-M-B6 (entry 117, table III)

An isocyanate of formula (VII) wherein R^(c) corresponds to fragment A17 of table II (1.35 mmol, 15 eq) was added to a suspension of the resin of example 19 (0.09 mmol, 1 eq) in dry dichloromethane (1 ml). The final suspension was shaken overnight at room temperature in a reactor (Quest 210™ or Miniblocks™). The resin was rinsed with a cycle of DMF, MeOH, DCM (3 times), DCM (3 times) and 1,4-dioxane (once) and dried under nitrogen flux. The resin was suspended in a solution of TFA-DCM (1:1, 2 ml) and shaken for 2 h at room temperature. The solution was collected and the resin was rinsed with DCM (collected as well), and a second cycle was performed. The final washing was performed with MeOH. All the collected organic layers were dried under reduced pressure affording compound A17-M-B6 (see entry 117 of table III below).

LCMS (HPLC Method 2): m/z 463 [M+H]⁺@r.t. 4.02 min. ¹H NMR (400 MHz, DMSO-d₆) δ=8.29 (s, 1 H), 8.26 (s, 1H), 8.07 (t, J=5.7 Hz, 1 H), 7.52 (d, J=3.0 Hz, 1 H), 7.28-7.33 (m, 2 H), 7.10 (d, J=1.8 Hz, 1 H), 6.77-6.85 (m, 2H), 6.46 (d, J=1.7 Hz, 1 H), 4.50 (tt, J=3.9, 6.9 Hz, 0 H), 3.70 (s, 4 H), 3.63 (ddd, J=1.3, 4.2, 12.8 Hz, 1 H).

Preparation of 7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-carboxylic acid (XI, where R1=OH)

LiOH.H₂O (63 mg, 1.5 mmol) was added to a solution of ethyl(7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl)acetate (XII, where R1=OCH₂CH₃) (0.26 g, 0.75 mmol) in a mixture tetrahydrofuran-water (1:1, 8 mL) and the reaction mixture was stirred at room temperature for 3 h. The organic phase was washed with dichloromethane (2×10 mL). The aqueous phase was acidified with hydrochloric acid (1 M) to reach pH<1 and extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na₂SO₄ and the solvent was evaporated under vacuum to obtain compound 7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-carboxylic acid (XII, where R1=OH) as an off-white solid (0.23 g, 75% yield).

LCMS (HPLC Method 2): m/z 321 [M+H]⁺@r.t. 2.52 min. ¹H NMR (400 MHz, DMSO-d₆) δ=12.63 (br. s., 1 H), 7.71 (br. s., 1 H), 7.14 (d, J=1.7 Hz, 1 H), 6.72 (d, J=1.7 Hz, 1 H), 4.54-4.66 (m, 1 H), 3.59-3.70 (m, 1 H), 3.32-3.38 (m, 1 H), 2.76 (d, J=7.0 Hz, 2 H).

Loading of the 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one scaffold onto the resin prepared as described previously.

A solution of 7-iodo-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-carboxylic acid (XI, where R1=OH) (0.92 g, 2.87 mmol), N,N-diisopropylethylamine (DIPEA) (0.99 ml, 5.76 mmol) and benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (1.5 g, 2.87 mmol) in dry N,N-dimethylacetamide (9 ml) was stirred for 30 min, then was added to resin of example 17 (1.44 mmol, 1 eq) and the final suspension was shaken for 24 h at room temperature. The resin was rinsed with a cycle of DMF, MeOH, DCM (3 times), DCM (3 times) and 1,4-dioxane (once) and dried under nitrogen flux. The resin was then used in the next step.

EXAMPLE 12 Preparation of A24-M-B6 (entry 135, table III)

A mixture of boronic acid of formula (XII), wherein R^(c) corresponds to the fragment A24 of table II (0.37 g, 3 mmol*), 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride complex with dichloromethane (1:1) (PdCl₂(dppf).CH₂Cl₂) (65 mg, 0.08 mmol), cesium carbonate (0.52 g, 1.6 mmol) and the resin from example 23 (0.2 mmol, 1 eq.) in a mixture dimethoxyethane-water (3:1, 2 mL) was shaken overnight at 80° C. in a reactor (Quest 210™). The resin was rinsed with a cycle of DMF, MeOH, DCM (3 times), DCM (3 times) and 1,4-dioxane (once) and dried under nitrogen flux. The resin was suspended in a solution of TFA-DCM (1:1, 2 ml) and shaken for 2 h at room temperature. The solution was collected and the resin was rinsed with DCM (collected as well), and a second cycle was performed. The final washing was performed with MeOH. All the collected organic layers were dried under reduced pressure affording compound A24-M-B6 (see entry 135 of table III below).

LCMS (HPLC Method 2): m/z 376 [M+H]⁺@r.t. 4.17 min. ¹H NMR (400 MHz, DMSO-d₆) δ=8.64 (d, J=6.3 Hz, 2H), 8.11 (s, 1 H), 8.05 (d, J=6.5 Hz, 2 H), 7.95 (d, J=1.6 Hz, 1 H), 7.88 (d, 1 H), 7.47 (d, J=1.7 Hz, 1 H), 7.23 (t, J=7.4 Hz, 2 H), 7.15 (t, J=7.3 Hz, 1 H), 7.10 (dd, J=1.5, 7.4 Hz, 2 H), 4.73 (tt, J=3.7, 7.1 Hz, 1 H), 3.68 (ddd, 1 H).

Following the procedure described in examples 4-6, 9-11, 14-15 and 16-24 and by using any proper reactant as per the process of the invention, the following compounds of table III were also prepared.

TABLE III HPLC HPLC Rt Entry Compound Method (min) [M + H]⁺ 1 A1-M-B1 2 5.17 323.2 2 A1-M-B2 2 4.49 295.2 3 A1-M-B6 2 6.04 398.3 4 A1-M-B7 2 5.06 352.3 5 A1-M-B8 2 4.27 380.3 6 A1-M-B9 2 6.05 364.3 7 A2-M-B1 2 4.53 329.2 8 A2-M-B2 2 3.06 301.2 9 A2-M-B3 2 5.31 357.3 10 A2-M-B4 2 4.15 398.3 11 A3-M-B1 2 3.92 372.2 12 A3-M-B2 2 2.8 344.2 13 A3-M-B5 2 3.77 411.3 14 A4-M-B1 2 4.08 392.2 15 A4-M-B10 2 3.72 461.3 16 A4-M-B11 2 3.8 461.3 17 A4-M-B2 2 2.86 364.2 18 A5-M-B1 2 3.95 357.2 19 A5-M-B12 1 2.54 412.3 20 A5-M-B16 1 3.19 432.3 21 A5-M-B17 1 2.38 356.3 22 A5-M-B18 1 3.6 424.3 23 A5-M-B2 2 2.72 329.2 24 A5-M-B21 1 3.34 432.3 25 A5-M-B22 1 3.55 424.3 26 A5-M-B23 1 2.94 384.3 27 A5-M-B24 1 3.28 410.3 28 A5-M-B26 1 2.99 396.3 29 A5-M-B5 2 3.74 396.3 30 A5-M-B7 2 3.11 386.3 31 A5-M-B7 1 2.34 386.3 32 A5-M-B8 2 2.72 413.3 33 A6-M-B1 2 4.18 321.2 34 A7-M-B1 2 3.99 360.2 35 A7-M-B12 1 2.62 415.3 36 A7-M-B13 1 2.7 373.3 37 A7-M-B14 1 3.11 421.3 38 A7-M-B16 1 3.33 435.3 39 A7-M-B17 1 2.48 359.2 40 A7-M-B18 1 3.64 427.3 41 A7-M-B19 1 2.49 371.2 42 A7-M-B2 2 3.7 332.2 43 A7-M-B20 1 3.35 435.3 44 A7-M-B21 1 3.38 435.3 45 A7-M-B22 1 3.59 427.3 46 A7-M-B23 1 3 387.3 47 A7-M-B24 1 3.33 413.3 48 A7-M-B25 1 2.73 373.3 49 A7-M-B26 1 3.06 399.3 50 A7-M-B27 1 2.61 371.2 51 A7-M-B7 1 2.43 389.3 52 A8-M-B1 2 3.96 396.2 53 A8-M-B2 2 3.5 368.2 54 A9-M-B1 2 4.04 375.2 55 A9-M-B14 1 3.19 436.3 56 A9-M-B15 1 3.04 402.3 57 A9-M-B16 1 3.38 450.3 58 A9-M-B17 1 2.53 374.3 59 A9-M-B18 1 3.69 442.3 60 A9-M-B19 1 2.56 386.3 61 A9-M-B2 2 3.68 347.2 62 A9-M-B20 1 3.43 450.3 63 A9-M-B21 1 3.47 450.3 64 A9-M-B22 1 3.66 442.3 65 A9-M-B23 1 3.08 402.3 66 A9-M-B24 1 3.41 428.3 67 A9-M-B26 1 3.13 414.3 68 A9-M-B27 1 2.67 386.3 69 A9-M-B7 1 2.48 404.3 70 A10-M-B2 2 1.34 265.2 71 A11-M-B6 2 2.7 398.3 72 A11-M-B7 2 1.06 352.3 73 A11-M-B8 2 3.32 379.3 74 A11-M-B9 2 2.52 364.3 75 A12-M-B13 1 1.99 319.3 76 A12-M-B14 1 2.43 367.3 77 A12-M-B16 1 2.71 381.3 78 A12-M-B20 1 2.73 381.3 79 A12-M-B21 1 2.79 381.3 80 A12-M-B22 1 3.03 373.3 81 A12-M-B7 2 3.29 335.3 82 A12-M-B8 2 2.69 362.3 83 A13-M-B7 2 2.81 334.2 84 A13-M-B8 2 1.26 361.3 85 A13-M-B9 2 3.12 346.3 86 A14-M-B7 2 3.84 389.2 87 A14-M-B8 2 3.03 416.3 88 A15-M-B12 1 2.61 417.3 89 A15-M-B13 1 2.68 375.2 90 A15-M-B14 1 3.07 423.2 91 A15-M-B15 1 2.92 389.3 92 A15-M-B16 1 3.28 437.3 93 A15-M-B18 1 3.59 429.3 94 A15-M-B19 1 2.52 373.2 95 A15-M-B20 1 3.3 437.3 96 A15-M-B21 1 3.32 437.3 97 A15-M-B22 1 3.52 429.3 98 A15-M-B23 1 2.97 389.3 99 A15-M-B24 1 3.28 415.3 100 A15-M-B25 1 2.72 375.2 101 A15-M-B26 1 3.02 401.3 102 A15-M-B27 1 2.6 373.2 103 A15-M-B7 1 2.44 391.2 104 A15-M-B8 2 2.85 418.3 105 A16-M-B14 1 3.32 424.3 106 A16-M-B18 1 3.83 430.4 107 A16-M-B20 1 3.56 438.3 108 A16-M-B21 1 3.6 438.3 109 A16-M-B22 1 3.81 430.4 110 A16-M-B23 1 3.23 390.3 111 A16-M-B24 1 3.54 416.4 112 A16-M-B27 1 2.82 374.3 113 A16-M-B8 2 2.89 419.4 114 A17-M-B14 1 2.89 448.3 115 A17-M-B21 1 3.17 462.3 116 A17-M-B24 1 3.11 440.3 117 A17-M-B6 2 4.02 462.3 118 A17-M-B8 2 2.72 443.3 119 A17-M-B9 2 3.97 428.3 120 A18-M-B5 2 3.62 399.3 121 A19-M-B5 2 4.38 388.3 122 A20-M-B1 2 5.13 333.2 123 A20-M-B6 2 5.98 408.2 124 A20-M-B7 2 4.99 362.2 125 A20-M-B8 2 3.33 389.2 126 A20-M-B9 2 5.99 374.3 127 A21-M-B1 2 4.61 344.2 128 A22-M-B1 2 5.12 355.3 129 A22-M-B2 2 4.4 327.2 130 A22-M-B6 2 5.87 430.3 131 A22-M-B7 2 4.94 384.3 132 A22-M-B8 2 4.14 411.3 133 A22-M-B9 2 5.88 396.3 135 A24-M-B6 2 4.17 375.3 136 A24-M-B7 2 2.45 329.3 137 A24-M-B8 2 1.97 356.3 138 A24-M-B9 2 4.07 341.3 139 A25-M-B1 2 6.16 315.3 140 A25-M-B2 2 4.58 287.2 141 A25-M-B6 2 6.23 390.3 142 A25-M-B7 2 5.2 344.3 143 A25-M-B8 2 4.3 371.3 144 A25-M-B9 2 6.24 356.3 145 A26-M-B1 2 5.9 353.2 146 A26-M-B2 2 4.48 325.2 147 A26-M-B6 2 5.96 428.3 148 A26-M-B7 2 5.04 382.3 149 A26-M-B8 2 4.22 409.3 150 A26-M-B9 2 5.98 394.3 151 A27-M-B1 2 6.48 357.2 152 A27-M-B2 2 4.98 329.2 153 A27-M-B6 2 6.5 432.2 154 A27-M-B7 2 5.57 386.2 155 A27-M-B8 2 4.72 413.3 156 A27-M-B9 2 6.54 398.3 157 A28-M-B1 2 6.92 416.3 158 A28-M-B2 2 5.52 388.3 159 A28-M-B6 2 6.9 491.3 160 A28-M-B7 2 6.07 445.3 161 A28-M-B8 2 5.16 472.4 162 A28-M-B9 2 6.95 457.4 163 A29-M-B1 2 5.12 263.2 164 A29-M-B2 2 3.51 235.2 165 A29-M-B6 2 5.35 338.3 166 A29-M-B7 2 4.14 292.3 167 A29-M-B8 2 3.35 319.3 168 A29-M-B9 2 5.31 304.3 169 A30-M-B1 2 6.8 331.3 170 A30-M-B2 2 5.11 303.3 171 A30-M-B6 2 6.76 406.3 172 A30-M-B7 2 5.76 360.3 173 A30-M-B8 2 4.78 387.4 174 A30-M-B9 2 6.82 372.4 175 A31-M-B1 2 5.92 325.2 176 A31-M-B2 2 4.45 297.2 177 A31-M-B6 2 5.98 400.3 178 A31-M-B7 2 5.02 354.3 179 A31-M-B8 2 4.17 381.3 180 A31-M-B9 2 5.99 366.3 181 A32-M-B1 2 6.4 359.2 182 A32-M-B2 2 4.92 331.2 183 A32-M-B6 2 6.41 434.3 184 A32-M-B7 2 5.5 388.2 185 A32-M-B8 2 4.7 415.3 186 A32-M-B9 2 6.45 400.3 187 A33-M-B6 2 5.42 380.2 188 A33-M-B7 2 4.33 334.2 189 A33-M-B8 3 3.88 361.2 190 A33-M-B9 2 5.39 346.3 191 A34-M-B6 2 5.55 374.3 192 A34-M-B7 2 4.48 328.3 193 A34-M-B8 3 4.11 355.3 194 A34-M-B9 2 5.49 340.3 195 A35-M-B7 2 4.62 371.3 196 A36-M-B12 1 3.02 425.3 197 A36-M-B14 1 3.44 431.3 198 A36-M-B15 1 3.33 397.3 199 A36-M-B16 1 3.63 445.3 200 A36-M-B17 1 2.91 369.3 201 A36-M-B20 1 3.65 445.3 202 A36-M-B21 1 3.65 445.3 203 A36-M-B22 1 3.85 437.3 204 A36-M-B26 1 3.4 409.3 205 A36-M-B7 1 2.86 399.3 206 A37-M-B12 1 2.3 403.2 207 A37-M-B13 1 2.34 361.2 208 A37-M-B14 1 2.77 409.2 209 A37-M-B15 1 2.61 375.2 210 A37-M-B16 1 3 423.2 211 A37-M-B17 1 2.14 347.2 212 A37-M-B18 1 3.33 415.3 213 A37-M-B19 1 2.17 359.2 214 A37-M-B20 1 3.02 423.2 215 A37-M-B21 1 3.05 423.2 216 A37-M-B22 1 3.26 415.3 217 A37-M-B23 1 2.65 375.2 218 A37-M-B24 1 2.98 401.3 219 A37-M-B25 1 2.37 361.2 220 A37-M-B26 1 2.7 387.2 221 A37-M-B27 1 2.26 359.2 222 A37-M-B7 1 2.11 377.2 223 A38-M-B12 1 2.75 411.3 224 A38-M-B13 1 2.84 369.3 225 A38-M-B14 1 3.21 417.3 226 A38-M-B15 1 3.07 383.3 227 A38-M-B16 1 3.41 431.3 228 A38-M-B17 1 2.63 355.3 229 A38-M-B18 1 3.7 423.3 230 A38-M-B19 1 2.66 367.3 231 A38-M-B20 1 3.43 431.3 232 A38-M-B21 1 3.46 431.3 233 A38-M-B22 1 3.65 423.3 234 A38-M-B23 1 3.1 383.3 235 A38-M-B24 1 3.41 409.3 236 A38-M-B25 1 2.87 369.3 237 A38-M-B26 1 3.16 395.3 238 A38-M-B27 1 2.74 367.3 239 A38-M-B7 1 2.58 385.3 240 A39-M-B12 1 2.33 422.3 241 A39-M-B13 1 2.39 380.3 242 A39-M-B14 1 2.79 428.3 243 A39-M-B15 1 2.64 394.3 244 A39-M-B16 1 3.02 442.3 245 A39-M-B18 1 3.32 434.3 246 A39-M-B19 1 2.22 378.2 247 A39-M-B20 1 3.02 442.3 248 A39-M-B21 1 3.04 442.3 249 A39-M-B22 1 3.24 434.3 250 A39-M-B23 1 2.67 394.3 251 A39-M-B24 1 2.98 420.3 252 A39-M-B25 1 2.42 380.3 253 A39-M-B26 1 2.72 406.3 254 A39-M-B27 1 2.32 378.2 255 A39-M-B7 1 2.18 396.3 256 A40-M-B12 1 2.31 403.2 257 A40-M-B13 1 2.36 361.2 258 A40-M-B14 1 2.8 409.2 259 A40-M-B15 1 2.63 375.2 260 A40-M-B16 1 3.04 423.2 261 A40-M-B18 1 3.38 415.3 262 A40-M-B19 1 2.17 359.2 263 A40-M-B20 1 3.06 423.2 264 A40-M-B21 1 3.1 423.2 265 A40-M-B22 1 3.31 415.3 266 A40-M-B23 1 2.67 375.2 267 A40-M-B24 1 3.03 401.3 268 A40-M-B25 1 2.39 361.2 269 A40-M-B26 1 2.73 387.2 270 A40-M-B27 1 2.27 359.2 271 A40-M-B7 1 2.13 377.2 272 A41-M-B12 1 2.88 433.3 273 A41-M-B13 1 2.97 391.3 274 A41-M-B14 1 3.36 439.3 275 A41-M-B15 1 3.22 405.3 276 A41-M-B16 1 3.56 453.3 277 A41-M-B18 1 3.8 445.3 278 A41-M-B19 1 2.78 389.2 279 A41-M-B20 1 3.59 453.3 280 A41-M-B21 1 3.6 453.3 281 A41-M-B22 1 3.8 445.3 282 A41-M-B23 1 3.26 405.3 283 A41-M-B24 1 3.57 431.3 284 A41-M-B25 1 3 391.3 285 A41-M-B26 1 3.31 417.3 286 A41-M-B27 1 2.87 389.2 287 A41-M-B7 1 2.68 407.2 288 A42-M-B12 1 2.89 425.3 289 A42-M-B13 1 2.99 383.3 290 A42-M-B14 1 3.38 431.3 291 A42-M-B15 1 3.23 397.3 292 A42-M-B16 1 3.56 445.3 293 A42-M-B18 1 3.84 437.3 294 A42-M-B19 1 2.8 381.3 295 A42-M-B20 1 3.59 445.3 296 A42-M-B21 1 3.63 445.3 297 A42-M-B22 1 3.82 437.3 298 A42-M-B23 1 3.27 397.3 299 A42-M-B24 1 3.57 423.3 300 A42-M-B25 1 3.02 383.3 301 A42-M-B26 1 3.33 409.3 302 A42-M-B27 1 2.9 381.3 303 A42-M-B7 1 2.73 399.3 304 A43-M-B12 1 2.84 449.2 305 A43-M-B14 1 3.3 455.2 306 A43-M-B15 1 3.16 421.2 307 A43-M-B16 1 3.5 469.2 308 A43-M-B18 1 3.76 461.3 309 A43-M-B19 1 2.74 405.2 310 A43-M-B20 1 3.53 469.2 311 A43-M-B21 1 3.55 469.2 312 A43-M-B22 1 3.75 461.3 313 A43-M-B23 1 3.21 421.2 314 A43-M-B24 1 3.5 447.3 315 A43-M-B25 1 2.95 407.2 316 A43-M-B26 1 3.25 433.2 317 A43-M-B27 1 2.83 405.2 318 A43-M-B7 1 2.66 423.2 319 A44-M-B13 1 2.26 429.3 320 A44-M-B14 1 2.74 381.3 321 A44-M-B15 1 2.54 347.3 322 A44-M-B16 1 2.98 395.3 323 A44-M-B17 1 2.04 319.3 324 A44-M-B20 1 3.02 395.3 325 A44-M-B21 1 3.08 395.3 326 A44-M-B22 1 3.3 387.3 327 A44-M-B25 1 2.29 333.3 328 A44-M-B26 1 2.65 359.3 329 A45-M-B12 1 2.66 391.3 330 A45-M-B13 1 2.77 349.3 331 A45-M-B14 1 3.21 397.3 332 A45-M-B15 1 3.05 363.3 333 A45-M-B17 1 2.52 335.3 334 A45-M-B20 1 3.45 411.3 335 A45-M-B21 1 3.5 411.3 336 A45-M-B22 1 3.72 403.4 337 A45-M-B25 1 2.81 349.3 338 A45-M-B26 1 3.15 375.3 339 A45-M-B7 1 2.46 365.3 340 A46-M-B12 1 2.34 422.3 341 A46-M-B13 1 2.4 380.3 342 A46-M-B14 1 2.8 428.3 343 A46-M-B15 1 2.65 394.3 344 A46-M-B16 1 3.03 442.3 345 A46-M-B17 1 2.21 366.2 346 A46-M-B18 1 3.25 434.3 347 A46-M-B19 1 2.23 378.2 348 A46-M-B20 1 3.04 442.3 349 A46-M-B25 1 2.42 380.3 350 A46-M-B26 1 2.73 406.3 351 A46-M-B27 1 2.32 378.2 352 A46-M-B7 1 2.18 396.3 353 A47-M-B13 1 2.61 369.3 354 A47-M-B14 1 3.06 417.3 355 A47-M-B15 1 2.89 383.3 356 A47-M-B16 1 3.26 431.3 357 A47-M-B17 1 2.38 355.3 358 A47-M-B18 1 3.58 423.3 359 A47-M-B19 1 2.4 367.3 360 A47-M-B20 1 3.31 431.3 361 A47-M-B21 1 3.35 431.3 362 A47-M-B22 1 3.55 423.3 363 A47-M-B23 1 2.92 383.3 364 A47-M-B24 1 3.27 409.3 365 A47-M-B25 1 2.64 369.3 366 A47-M-B26 1 2.99 395.3 367 A47-M-B27 1 2.52 367.3 368 A47-M-B7 1 2.35 385.3 369 A48-M-B12 1 2.77 411.3 370 A48-M-B13 1 2.84 369.3 371 A48-M-B14 1 3.23 417.3 372 A48-M-B15 1 3.09 383.3 373 A48-M-B16 1 3.44 431.3 374 A48-M-B17 1 2.64 355.3 375 A48-M-B19 1 2.67 367.3 376 A48-M-B20 1 3.45 431.3 377 A48-M-B21 1 3.48 431.3 378 A48-M-B22 1 3.67 423.3 379 A48-M-B26 1 3.16 395.3 380 A48-M-B7 1 2.6 385.3 381 A49-M-B12 1 2.78 403.3 382 A49-M-B13 1 2.89 361.3 383 A49-M-B14 1 3.31 409.3 384 A49-M-B15 1 3.16 375.3 385 A49-M-B16 1 3.51 423.3 386 A49-M-B17 1 2.66 347.3 387 A49-M-B18 1 3.82 415.4 388 A49-M-B19 1 2.68 359.3 389 A49-M-B20 1 3.56 423.3 390 A49-M-B21 1 3.59 423.3 391 A49-M-B22 1 3.79 415.4 392 A49-M-B23 1 3.2 375.3 393 A49-M-B24 1 3.53 401.3 394 A49-M-B25 1 2.92 361.3 395 A49-M-B26 1 3.26 387.3 396 A49-M-B27 1 2.8 359.3 397 A49-M-B7 1 2.6 377.3 398 A50-M-B12 1 2.58 391.3 399 A50-M-B13 1 2.66 349.3 400 A50-M-B14 1 3.15 397.3 401 A50-M-B15 1 2.95 363.3 402 A50-M-B16 1 3.33 411.3 403 A50-M-B17 1 2.4 335.3 404 A50-M-B20 1 3.39 411.3 405 A50-M-B21 1 3.44 411.3 406 A50-M-B22 1 3.66 403.4 407 A50-M-B25 1 2.72 349.3 408 A50-M-B26 1 3.06 375.3 409 A51-M-B12 1 2.37 377.3 410 A51-M-B13 1 2.44 335.3 411 A51-M-B14 1 2.91 383.3 412 A51-M-B15 1 2.73 349.3 413 A51-M-B16 1 3.15 397.3 414 A51-M-B17 1 2.2 321.3 415 A51-M-B22 1 3.48 389.3 416 A51-M-B25 1 2.47 335.3 417 A51-M-B26 1 2.83 361.3 418 A51-M-B27 1 2.34 333.3 419 A52-M-B12 1 2.89 425.3 420 A52-M-B13 1 2.99 383.3 421 A52-M-B14 1 3.38 431.3 422 A52-M-B15 1 3.24 397.3 423 A52-M-B16 1 3.56 445.3 424 A52-M-B18 1 3.83 437.3 425 A52-M-B19 1 2.8 381.3 426 A52-M-B20 1 3.59 445.3 427 A52-M-B21 1 3.62 445.3 428 A52-M-B22 1 3.82 437.3 429 A52-M-B23 1 3.28 397.3 430 A52-M-B24 1 3.57 423.3 431 A52-M-B25 1 3.03 383.3 432 A52-M-B26 1 3.33 409.3 433 A52-M-B27 1 2.91 381.3 434 A52-M-B7 1 2.72 399.3 435 A53-M-B12 1 2.26 433.3 436 A53-M-B13 1 2.31 391.3 437 A53-M-B14 1 2.75 439.3 438 A53-M-B15 1 2.57 405.3 439 A53-M-B16 1 2.98 453.3 440 A53-M-B20 1 3.01 453.3 441 A53-M-B21 1 3 453.3 442 A53-M-B26 1 2.65 417.3 443 A53-M-B7 1 2.08 407.2 444 A54-M-B13 1 2.38 335.3 445 A54-M-B14 1 2.88 383.3 446 A54-M-B15 1 2.67 349.3 447 A54-M-B20 1 3.15 397.3 448 A54-M-B21 1 3.2 397.3 449 A54-M-B26 1 2.78 361.3 450 A55-M-B12 1 2.55 433.3 451 A55-M-B13 1 2.62 391.3 452 A55-M-B14 1 3.06 439.3 453 A55-M-B15 1 2.88 405.3 454 A55-M-B16 1 3.26 453.3 455 A55-M-B17 1 2.4 377.2 456 A55-M-B18 1 3.51 445.3 457 A55-M-B19 1 2.43 389.2 458 A55-M-B20 1 3.29 453.3 459 A55-M-B21 1 3.33 453.3 460 A55-M-B22 1 3.53 445.3 461 A55-M-B23 1 2.93 405.3 462 A55-M-B25 1 2.65 391.3 463 A55-M-B26 1 2.98 417.3 464 A55-M-B27 1 2.53 389.2 465 A55-M-B7 1 2.36 407.2 466 A56-M-B13 1 2.99 391.3 467 A56-M-B14 1 3.38 439.3 468 A56-M-B15 1 3.23 405.3 469 A56-M-B16 1 3.58 453.3 470 A56-M-B18 1 3.86 445.3 471 A56-M-B19 1 2.79 389.2 472 A56-M-B20 1 3.61 453.3 473 A56-M-B21 1 3.62 453.3 474 A56-M-B22 1 3.81 445.3 475 A56-M-B23 1 3.28 405.3 476 A56-M-B24 1 3.59 431.3 477 A56-M-B25 1 3.01 391.3 478 A56-M-B26 1 3.33 417.3 479 A56-M-B27 1 2.89 389.2 480 A56-M-B7 1 2.7 407.2 481 A57-M-B12 1 3.09 425.3 482 A57-M-B13 1 3.2 383.3 483 A57-M-B14 1 3.53 431.3 484 A57-M-B15 1 3.42 397.3 485 A57-M-B16 1 3.71 445.3 486 A57-M-B18 1 3.97 437.3 487 A57-M-B19 1 3.05 381.3 488 A57-M-B20 1 3.73 445.3 489 A57-M-B21 1 3.74 445.3 490 A57-M-B22 2 5.77 437.3 491 A57-M-B23 1 3.45 397.3 492 A57-M-B24 1 3.72 423.3 493 A57-M-B25 1 3.23 383.3 494 A57-M-B26 1 3.49 409.3 495 A57-M-B27 1 3.13 381.3 496 A57-M-B7 1 2.95 399.3 497 A58-M-B13 1 2.53 375.2 498 A58-M-B15 1 2.8 389.3 499 A58-M-B16 1 3.16 437.3 500 A58-M-B17 1 2.32 361.2 501 A58-M-B20 1 3.19 437.3 502 A58-M-B21 1 3.21 437.3 503 A58-M-B25 1 2.56 375.2 504 A58-M-B26 1 2.88 401.3 505 A59-M-B12 1 2.67 449.2 506 A59-M-B13 1 2.75 407.2 507 A59-M-B14 1 3.19 455.2 508 A59-M-B15 1 3.01 421.2 509 A59-M-B16 1 3.38 469.2 510 A59-M-B18 1 3.69 461.3 511 A59-M-B19 1 2.55 405.2 512 A59-M-B20 1 3.41 469.2 513 A59-M-B21 1 3.46 469.2 514 A59-M-B22 1 3.65 461.3 515 A59-M-B23 1 3.06 421.2 516 A59-M-B25 1 2.78 407.2 517 A59-M-B26 1 3.12 433.2 518 A59-M-B27 1 2.65 405.2 519 A59-M-B7 1 2.47 423.2 520 A60-M-B12 1 2.34 377.3 521 A60-M-B13 1 2.4 335.3 522 A60-M-B14 1 2.88 383.3 523 A60-M-B15 1 2.69 349.3 524 A60-M-B16 1 3.1 397.3 525 A60-M-B20 1 3.15 397.3 526 A60-M-B21 1 3.21 397.3 527 A60-M-B22 1 3.44 389.3 528 A60-M-B23 1 2.73 349.3 529 A60-M-B25 1 2.43 335.3 530 A60-M-B26 1 2.81 361.3 531 A60-M-B27 1 2.3 333.3 532 A61-M-B13 1 2.52 335.3 533 A61-M-B14 1 2.98 383.3 534 A61-M-B15 1 2.8 349.3 535 A61-M-B16 1 3.2 397.3 536 A61-M-B17 1 2.27 321.3 537 A61-M-B19 1 2.31 333.3 538 A61-M-B20 1 3.25 397.3 539 A61-M-B21 1 3.3 397.3 540 A61-M-B26 1 2.9 361.3 541 A62-M-B12 1 2.42 397.3 542 A62-M-B13 1 2.49 355.3 543 A62-M-B14 1 2.91 403.3 544 A62-M-B15 1 2.75 369.3 545 A62-M-B16 1 3.13 417.3 546 A62-M-B17 1 2.26 341.3 547 A62-M-B18 1 3.46 409.3 548 A62-M-B19 1 2.29 353.3 549 A62-M-B20 1 3.16 417.3 550 A62-M-B21 1 3.2 417.3 551 A62-M-B22 1 3.39 409.3 552 A62-M-B23 1 2.78 369.3 553 A62-M-B24 1 3.12 395.3 554 A62-M-B25 1 2.51 355.3 555 A62-M-B26 1 2.83 381.3 556 A62-M-B27 1 2.38 353.3 557 A62-M-B7 1 2.24 371.3 558 A63-M-B12 1 2.96 429.3 559 A63-M-B13 1 3.07 387.3 560 A63-M-B14 1 3.41 435.3 561 A63-M-B15 1 3.3 401.3 562 A63-M-B16 1 3.6 449.3 563 A63-M-B17 1 2.86 373.3 564 A63-M-B18 1 3.88 441.3 565 A63-M-B19 1 2.89 385.3 566 A63-M-B20 1 3.63 449.3 567 A63-M-B21 1 3.64 449.3 568 A63-M-B22 1 3.83 441.3 569 A63-M-B26 1 3.38 413.3 570 A63-M-B27 1 2.99 385.3 571 A63-M-B7 1 2.82 403.3 572 A64-M-B12 1 2.34 415.3 573 A64-M-B14 1 2.84 421.3 574 A64-M-B15 1 2.67 387.3 575 A64-M-B16 1 3.06 435.3 576 A64-M-B17 1 2.22 359.2 577 A64-M-B20 1 3.09 435.3 578 A64-M-B21 1 3.13 435.3 579 A64-M-B22 1 3.33 427.3 580 A64-M-B26 1 2.75 399.3 581 A64-M-B27 1 2.34 371.2 582 A64-M-B7 1 2.19 389.3 583 A65-M-B12 1 2.51 389.3 584 A65-M-B14 1 3.05 395.3 585 A65-M-B15 1 2.86 361.3 586 A65-M-B16 1 3.26 409.3 587 A65-M-B17 1 2.34 333.3 588 A65-M-B18 1 3.59 401.3 589 A65-M-B19 1 2.37 345.3 590 A65-M-B20 1 3.3 409.3 591 A65-M-B21 1 3.34 409.3 592 A65-M-B22 1 3.57 401.3 593 A65-M-B26 1 2.97 373.3 594 A65-M-B7 1 2.3 363.3 595 A66-M-B12 1 2.56 449.2 596 A66-M-B14 1 3.08 455.2 597 A66-M-B15 1 2.9 421.2 598 A66-M-B16 1 3.29 469.2 599 A66-M-B20 1 3.32 469.2 600 A66-M-B21 1 3.35 469.2 601 A66-M-B25 1 2.66 407.2 602 A66-M-B26 1 3.02 433.2 603 A67-M-B12 1 2.5 433.3 604 A67-M-B14 1 3 439.3 605 A67-M-B15 1 2.84 405.3 606 A67-M-B16 1 3.21 453.3 607 A67-M-B18 1 3.45 445.3 608 A67-M-B19 1 2.37 389.2 609 A67-M-B20 1 3.24 453.3 610 A67-M-B21 1 3.28 453.3 611 A67-M-B26 1 2.92 417.3 612 A67-M-B27 1 2.49 389.2 613 A67-M-B7 1 2.32 407.2 614 A68-M-B12 1 2.43 431.2 615 A68-M-B14 1 2.95 437.2 616 A68-M-B15 1 2.78 403.2 617 A68-M-B16 1 3.17 451.2 618 A68-M-B17 1 2.29 375.2 619 A68-M-B18 1 3.47 443.3 620 A68-M-B19 1 2.31 387.2 621 A68-M-B20 1 3.19 451.2 622 A68-M-B21 1 3.24 451.2 623 A68-M-B26 1 2.87 415.2 624 A68-M-B27 1 2.41 387.2 625 A68-M-B7 1 2.25 405.2 626 A69-M-B14 1 2.61 369.3 627 A69-M-B15 1 2.38 335.3 628 A69-M-B16 1 2.85 383.3 629 A69-M-B20 1 2.9 383.3 630 A69-M-B21 1 2.95 383.3 631 A69-M-B25 1 2.15 321.3 632 A69-M-B26 1 2.5 347.3 633 A70-M-B12 1 2.62 415.3 634 A70-M-B14 1 3.12 421.3 635 A70-M-B15 1 2.97 387.3 636 A70-M-B16 1 3.33 435.3 637 A70-M-B17 1 2.48 359.2 638 A70-M-B18 1 3.63 427.3 639 A70-M-B19 1 2.5 371.2 640 A70-M-B20 1 3.35 435.3 641 A70-M-B21 1 3.37 435.3 642 A70-M-B26 1 3.06 399.3 643 A70-M-B27 1 2.61 371.2 644 A70-M-B7 1 2.43 389.3 645 A71-M-B14 1 2.58 369.3 646 A71-M-B16 1 2.84 383.3 647 A71-M-B20 1 2.87 383.3 648 A71-M-B21 1 2.93 383.3 649 A71-M-B25 1 2.11 321.3 650 A72-M-B14 1 2.52 421.3 651 A72-M-B16 1 2.74 435.3 652 A72-M-B18 1 3.06 427.3 653 A72-M-B20 1 2.75 435.3 654 A72-M-B21 1 2.77 435.3 655 A72-M-B27 1 2.07 371.3 656 A73-M-B12 1 2.66 430.3 657 A73-M-B14 1 3.17 436.3 658 A73-M-B17 1 2.17 374.3 659 A73-M-B20 1 3.4 450.3 660 A73-M-B21 1 3.45 450.3 661 A73-M-B24 1 3.38 428.3 662 A73-M-B26 1 3.11 414.3 663 A74-M-B16 1 2.87 453.3 664 A74-M-B17 1 2.04 377.2 665 A75-M-B18 1 2.95 399.3 666 A75-M-B19 1 1.91 343.2 667 A75-M-B20 1 2.72 407.3 668 A75-M-B21 1 2.75 407.3 669 A75-M-B22 1 2.98 399.3 670 A75-M-B23 1 2.34 359.3 671 A75-M-B24 1 2.68 385.3 672 A75-M-B25 1 2.09 345.2 673 A75-M-B27 1 1.98 343.2 674 A76-M-B18 1 2.69 410.3 675 A76-M-B19 1 1.7 354.2 676 A76-M-B20 1 2.45 418.3 677 A76-M-B21 1 2.5 418.3 678 A76-M-B22 1 2.72 410.3 679 A76-M-B23 1 2.06 370.3 680 A76-M-B24 1 2.4 396.3 681 A76-M-B25 1 1.85 356.3 682 A77-M-B14 1 2.64 421.3 683 A77-M-B16 1 2.9 435.3 684 A77-M-B18 1 3.2 427.3 685 A77-M-B20 1 2.89 435.3 686 A77-M-B21 1 2.92 435.3 687 A77-M-B27 1 2.19 371.3 688 A78-M-B12 1 2.69 442.3 689 A78-M-B14 1 3.16 448.3 690 A78-M-B15 1 3.02 414.3 691 A78-M-B16 1 3.38 462.3 692 A78-M-B17 1 2.57 386.3 693 A78-M-B18 1 3.65 454.3 694 A78-M-B19 1 2.59 398.3 695 A78-M-B20 1 3.38 462.3 696 A78-M-B21 1 3.42 462.3 697 A78-M-B22 1 3.62 454.3 698 A78-M-B23 1 3.07 414.3 699 A78-M-B24 1 3.37 440.3 700 A78-M-B26 1 3.12 426.3 701 A78-M-B7 1 2.51 416.3 702 A79-M-B14 1 3.69 466.3 703 A79-M-B18 1 4.09 472.3 704 A79-M-B21 1 3.9 480.3 705 A79-M-B22 1 4.07 472.3 706 A79-M-B24 1 3.86 458.3 707 A79-M-B26 1 3.65 444.3 708 A80-M-B14 1 3.66 470.2 709 A80-M-B15 1 3.56 436.2 710 A80-M-B18 1 4.06 476.3 711 A80-M-B19 1 3.19 420.2 712 A80-M-B21 1 3.87 484.2 713 A80-M-B22 1 4.04 476.3 714 A80-M-B24 1 3.87 462.3 715 A81-M-B14 1 3.64 466.3 716 A81-M-B18 1 4.06 472.3 717 A81-M-B19 1 3.11 416.2 718 A81-M-B21 1 3.88 480.3 719 A81-M-B22 1 4.06 472.3 720 A81-M-B24 1 3.83 458.3 721 A82-M-B14 1 3.4 446.3 722 A82-M-B18 1 3.86 452.4 723 A82-M-B19 1 2.8 396.3 724 A82-M-B20 1 3.62 460.3 725 A82-M-B21 1 3.66 460.3 726 A82-M-B22 1 3.86 452.4 727 A82-M-B24 1 3.59 438.3 728 A83-M-B14 1 3.45 446.3 729 A83-M-B18 1 3.89 452.4 730 A83-M-B19 1 2.87 396.3 731 A83-M-B20 1 3.65 460.3 732 A83-M-B22 1 3.89 452.4 733 A83-M-B24 1 3.64 438.3 734 A84-M-B14 1 3.03 432.3 735 A84-M-B18 1 3.58 438.3 736 A84-M-B19 1 2.38 382.3 737 A84-M-B20 1 3.27 446.3 738 A84-M-B21 1 3.32 446.3 739 A84-M-B22 1 3.54 438.3 740 A85-M-B14 1 3.56 450.3 741 A85-M-B17 1 3.04 388.3 742 A85-M-B20 1 3.76 464.3 743 A85-M-B21 1 3.79 464.3 744 A85-M-B22 2 5.71 456.3 745 A86-M-B14 1 3.02 410.3 746 A86-M-B20 1 3.27 424.3 747 A86-M-B21 1 3.32 424.3 748 A86-M-B25 1 2.61 362.3 749 A87-M-B14 1 3.33 446.3 750 A87-M-B20 1 3.55 460.3 751 A88-M-B14 1 3.31 454.3 752 A88-M-B16 1 3.49 468.3 753 A88-M-B17 1 2.63 392.2 754 A88-M-B19 1 2.66 404.2 755 A88-M-B20 1 3.53 468.3 756 A88-M-B21 1 3.57 468.3 757 A89-M-B14 1 2.64 422.3 758 A89-M-B20 1 2.91 436.3 759 A89-M-B21 1 2.97 436.3 760 A90-M-B13 1 1.89 349.3 761 A90-M-B16 1 2.56 411.3 762 A90-M-B20 1 2.6 411.3 763 A90-M-B21 1 2.68 411.3 764 A91-M-B14 1 2.4 407.3 765 A91-M-B16 1 2.68 421.3 766 A91-M-B18 1 2.99 413.3 767 A91-M-B20 1 2.65 421.3 768 A91-M-B21 1 2.69 421.3 769 A91-M-B26 1 2.35 385.3 770 A92-M-B12 1 3.15 446.3 771 A92-M-B14 1 3.58 452.2 772 A92-M-B17 1 3.05 390.2 773 A92-M-B20 1 3.78 466.3 774 A92-M-B21 1 3.8 466.3 775 A92-M-B22 1 3.97 458.3 776 A92-M-B24 1 3.78 444.3 777 A92-M-B26 1 3.56 430.3 778 A92-M-B7 1 2.98 420.2 779 A93-M-B14 1 3.41 452.2 780 A93-M-B16 1 3.6 466.3 781 A93-M-B17 1 2.82 390.2 782 A93-M-B20 1 3.63 466.3 783 A93-M-B21 1 3.66 466.3 784 A93-M-B22 1 3.85 458.3 785 A93-M-B24 1 3.63 444.3 786 A93-M-B26 1 3.37 430.3 787 A93-M-B27 1 2.96 402.2 788 A93-M-B7 1 2.76 420.2 789 A94-M-B14 1 3.58 452.2 790 A94-M-B17 1 3.04 390.2 791 A94-M-B21 1 3.81 466.3 792 A94-M-B24 1 3.78 444.3 793 A94-M-B26 1 3.55 430.3 794 A95-M-B14 1 3.16 432.3 795 A95-M-B20 1 3.39 446.3 796 A95-M-B21 1 3.45 446.3 797 A95-M-B24 1 3.37 424.3 798 A95-M-B26 1 3.09 410.3 799 A96-M-B14 1 3.36 432.3 800 A96-M-B20 1 3.58 446.3 801 A96-M-B21 1 3.62 446.3 802 A96-M-B22 1 3.81 438.3 803 A96-M-B24 1 3.57 424.3 804 A97-M-B12 1 2.59 442.3 805 A97-M-B14 1 3.1 448.3 806 A97-M-B16 1 3.26 462.3 807 A97-M-B17 1 2.46 386.3 808 A97-M-B18 1 3.56 454.3 809 A97-M-B20 1 3.29 462.3 810 A97-M-B22 1 3.52 454.3 811 A97-M-B24 1 3.26 440.3 812 A97-M-B26 1 3.02 426.3 813 A98-M-B14 1 2.97 443.3 814 A98-M-B17 1 2.4 381.3 815 A98-M-B20 1 3.2 457.3 816 A98-M-B22 1 3.4 449.3 817 A98-M-B24 1 3.21 435.3 818 A98-M-B7 1 2.35 411.3 819 A99-M-B14 1 3.86 466.3 820 A99-M-B20 1 3.99 480.3 821 A99-M-B22 1 4.17 472.3 822 A99-M-B24 1 3.98 458.3 823 A99-M-B26 1 3.79 444.3 824 A100-M-B14 1 3.65 446.3 825 A100-M-B22 1 4.04 452.4 826 A100-M-B24 1 3.84 438.3 827 A100-M-B26 1 3.62 424.3 828 A101-M-B14 1 3.33 412.3 829 A101-M-B19 1 2.71 362.3 830 A101-M-B20 1 3.54 426.3 831 A101-M-B21 1 3.59 426.3 832 A101-M-B22 1 3.8 418.4 833 A102-M-B14 1 3.29 436.3 834 A102-M-B17 1 2.67 374.3 835 A102-M-B19 1 2.69 386.3 836 A102-M-B20 1 3.51 450.3 837 A102-M-B21 1 3.55 450.3 838 A102-M-B22 1 3.74 442.3 839 A103-M-B14 1 2.95 398.3 840 A103-M-B20 1 3.21 412.3 841 A103-M-B21 1 3.27 412.3 842 A103-M-B22 1 3.5 404.4 843 A104-M-B16 1 3.36 460.3 844 A104-M-B22 1 3.68 452.4 845 A105-M-B14 1 3.65 446.3 846 A105-M-B20 1 3.83 460.3 847 A105-M-B21 1 3.86 460.3 848 A105-M-B22 1 4.05 452.4 849 A106-M-B14 1 3.64 446.3 850 A106-M-B16 1 3.82 460.3 851 A106-M-B17 1 3.12 384.3 852 A106-M-B20 1 3.85 460.3 853 A106-M-B21 1 3.87 460.3 854 A106-M-B24 1 3.84 438.3 855 A106-M-B26 1 3.63 424.3 856 A107-M-B14 1 3.67 466.3 857 A107-M-B16 1 3.83 480.3 858 A107-M-B24 1 3.91 458.3 859 A107-M-B26 1 3.65 444.3 860 A108-M-B20 1 3.81 437.3 861 A108-M-B25 1 3.28 375.3 862 A108-M-B27 1 3.17 373.3 863 A109-M-B13 1 2.47 407.2 864 A109-M-B16 1 3.12 469.2 865 A110-M-B14 1 3.57 450.3 866 A110-M-B17 1 3.03 388.3 867 A110-M-B20 1 3.76 464.3 868 A111-M-B14 1 3.59 454.3 869 A111-M-B17 1 3.05 392.2 870 A111-M-B22 1 3.99 460.3 871 A112-M-B16 1 2.55 369.3 872 A112-M-B21 1 2.64 369.3 873 A113-M-B16 1 2.66 419.3 874 A114-M-B16 1 2.38 405.3 875 A115-M-B16 1 2.59 419.3 876 A116-M-B20 1 2.39 385.3 877 A116-M-B21 1 2.48 385.3 878 A117-M-B20 1 2.59 428.3 879 A118-M-B20 1 2.69 440.3 880 A118-M-B21 1 2.76 440.3 881 A119-M-B20 1 2.87 398.3 882 A120-M-B21 1 3.32 412.3 883 A121-M-B21 1 2.53 414.3 884 A122-M-B21 1 2.03 433.3 885 A122-M-B22 1 2.21 425.3 886 A123-M-B25 1 2.16 345.2 887 A20-M-B14 1 3.92 394.2 888 A20-M-B17 1 3.41 332.2 889 A20-M-B19 1 3.41 344.2 890 A20-M-B24 1 4.09 386.3 891 A20-M-B25 1 3.63 346.2 892 A20-M-B26 1 3.88 372.2 893 A20-M-B31 1 3.31 332.2 894 A20-M-B32 1 4.07 374.3 895 A20-M-B33 1 2.59 450.3 896 A20-M-B35 1 3.24 318.2 897 A20-M-B36 1 3.93 394.2 898 A20-M-B39 1 2.4 395.2 899 A20-M-B40 1 3.67 384.2 900 A20-M-B42 1 3.39 376.2 901 A20-M-B56 1 2.42 387.3 902 A20-M-B59 1 2.44 401.3 903 A33-M-B14 4 1.172 366.1 904 A33-M-B22 4 1.33 372.2 905 A33-M-B28 4 0.929 360.1 906 A33-M-B29 4 0.645 367.1 907 A33-M-B30 4 1.205 384.1 908 A124-M-B9 4 0.655 341.2 909 A125-M-B9 4 0.74 355.2 910 A126-M-B9 4 1.018 356.2 911 A127-M-B14 4 1.29 378.2 912 A127-M-B19 1 3.06 328.2 913 A127-M-B22 4 1.405 384.2 914 A127-M-B24 1 3.79 370.3 915 A127-M-B25 1 3.28 330.3 916 A127-M-B26 1 3.56 356.3 917 A127-M-B28 4 1 372.2 918 A127-M-B29 4 0.757 379.1 919 A127-M-B30 4 1.279 396.1 920 A127-M-B31 1 2.95 316.2 921 A127-M-B32 1 3.8 358.3 922 A127-M-B33 1 2.28 434.3 923 A127-M-B36 1 3.63 378.3 924 A127-M-B37 1 3.83 378.3 925 A127-M-B38 1 2.1 401.3 926 A127-M-B39 1 2.06 379.2 927 A127-M-B40 1 3.35 368.2 928 A127-M-B41 1 2.68 399.3 929 A127-M-B42 1 3.04 360.3 930 A127-M-B43 1 3.59 344.3 931 A127-M-B46 1 3.38 344.3 932 A127-M-B47 1 3.6 382.2 933 A127-M-B48 1 3.36 342.3 934 A127-M-B49 1 2.26 397.3 935 A127-M-B50 1 3.12 342.3 936 A127-M-B51 1 2.9 358.2 937 A127-M-B52 1 3.62 364.2 938 A127-M-B53 1 2.12 413.3 939 A127-M-B54 1 3.04 410.3 940 A127-M-B56 1 2.08 371.3 941 A127-M-B57 1 1.74 454.4 942 A127-M-B58 1 2.79 435.2 943 A127-M-B60 1 2.09 359.3 944 A127-M-B7 1 2.96 346.2 945 A127-M-B9 4 1.311 358.2 946 A128-M-B14 4 1.23 378.2 947 A128-M-B14 1 3.56 378.3 948 A128-M-B17 1 2.98 316.2 949 A128-M-B19 1 2.98 328.2 950 A128-M-B22 4 1.401 384.2 951 A128-M-B25 1 3.24 330.3 952 A128-M-B26 1 3.5 356.3 953 A128-M-B28 4 0.952 372.2 954 A128-M-B29 4 0.73 379.1 955 A128-M-B30 4 1.268 396.1 956 A128-M-B31 1 2.9 316.2 957 A128-M-B32 1 3.76 358.3 958 A128-M-B33 1 2.26 434.3 959 A128-M-B34 1 3.23 374.2 960 A128-M-B35 1 2.79 302.2 961 A128-M-B36 1 3.56 378.3 962 A128-M-B37 1 3.77 378.3 963 A128-M-B38 1 2.08 401.3 964 A128-M-B39 1 2.03 379.2 965 A128-M-B40 1 3.29 368.2 966 A128-M-B41 1 2.64 399.3 967 A128-M-B42 1 2.98 360.3 968 A128-M-B43 1 3.54 344.3 969 A128-M-B45 1 3.52 370.3 970 A128-M-B46 1 3.35 344.3 971 A128-M-B47 1 3.51 382.2 972 A128-M-B48 1 3.31 342.3 973 A128-M-B49 1 2.21 397.3 974 A128-M-B50 1 3.08 342.3 975 A128-M-B51 1 2.86 358.2 976 A128-M-B54 1 3 410.3 977 A128-M-B55 1 3.06 438.3 978 A128-M-B56 1 2.1 371.3 979 A128-M-B57 1 1.75 454.4 980 A128-M-B58 1 2.76 435.2 981 A128-M-B59 1 2.1 385.3 982 A128-M-B60 1 2.08 359.3 983 A128-M-B7 1 2.89 346.2 984 A128-M-B9 4 1.304 358.2 985 A129-M-B14 4 1.242 378.2 986 A129-M-B22 4 1.399 384.2 987 A129-M-B28 4 0.96 372.2 988 A129-M-B29 4 0.752 379.1 989 A129-M-B30 4 1.31 396.1 990 A129-M-B9 4 1.303 358.2 991 A130-M-B9 4 0.984 366.2 992 A131-M-B9 4 1.164 382.2 993 A132-M-B14 4 1.16 404.2 994 A132-M-B22 4 1.309 410.2 995 A132-M-B28 4 0.878 398.2 996 A132-M-B29 4 0.693 405.1 997 A132-M-B30 4 1.24 422.1 998 A132-M-B9 4 1.219 384.2 999 A133-M-B14 4 1.406 428.2 1000 A133-M-B22 4 1.6 434.2 1001 A133-M-B28 4 1.158 422.2 1002 A133-M-B29 4 0.95 429.1 1003 A133-M-B30 4 1.427 446.1 1004 A133-M-B9 4 1.473 408.2 1005 A134-M-B14 4 1.45 444.1 1006 A134-M-B22 4 1.593 450.2 1007 A134-M-B28 4 1.206 438.2 1008 A134-M-B29 4 1.002 445.1 1009 A134-M-B30 4 1.471 462.1 1010 A134-M-B9 4 1.516 424.2 1011 A135-M-B9 4 1.526 424.2 1012 A136-M-B9 4 0.674 355.2 1013 A137-M-B14 4 1.314 374.2 1014 A137-M-B14 1 3.76 374.3 1015 A137-M-B22 4 1.477 380.2 1016 A137-M-B24 1 3.93 366.3 1017 A137-M-B25 1 3.45 326.3 1018 A137-M-B26 1 3.7 352.3 1019 A137-M-B28 4 1.08 368.2 1020 A137-M-B29 4 0.808 375.2 1021 A137-M-B30 4 1.346 392.2 1022 A137-M-B32 1 3.95 354.3 1023 A137-M-B33 1 2.4 430.3 1024 A137-M-B34 1 3.42 370.3 1025 A137-M-B35 1 3.01 298.2 1026 A137-M-B36 1 3.77 374.3 1027 A137-M-B39 1 2.19 375.3 1028 A137-M-B40 1 3.49 364.3 1029 A137-M-B43 1 3.73 340.3 1030 A137-M-B48 1 3.5 338.3 1031 A137-M-B49 1 2.4 393.3 1032 A137-M-B50 1 3.27 338.3 1033 A137-M-B52 1 3.76 360.3 1034 A137-M-B54 1 3.19 406.3 1035 A137-M-B55 1 3.24 434.3 1036 A137-M-B56 1 2.25 367.3 1037 A137-M-B58 1 2.93 431.3 1038 A137-M-B59 1 2.25 381.3 1039 A138-M-B14 4 1.206 390.2 1040 A138-M-B22 4 1.43 396.2 1041 A138-M-B28 4 0.926 384.2 1042 A138-M-B29 4 0.726 391.2 1043 A138-M-B30 4 1.23 408.2 1044 A139-M-B14 1 3.75 396.2 1045 A139-M-B17 1 3.22 334.2 1046 A139-M-B19 1 3.23 346.2 1047 A139-M-B22 4 1.441 402.2 1048 A139-M-B24 1 3.93 388.3 1049 A139-M-B25 1 3.46 348.2 1050 A139-M-B26 1 3.71 374.3 1051 A139-M-B28 4 1.023 390.2 1052 A139-M-B29 4 0.822 397.1 1053 A139-M-B30 4 1.32 414.1 1054 A139-M-B31 1 3.12 334.2 1055 A139-M-B32 1 3.91 376.3 1056 A139-M-B33 1 2.45 452.3 1057 A139-M-B35 1 3.03 320.2 1058 A139-M-B36 1 3.77 396.2 1059 A139-M-B37 1 3.95 396.2 1060 A139-M-B38 1 2.29 419.3 1061 A139-M-B39 1 2.23 397.2 1062 A139-M-B40 1 3.51 386.2 1063 A139-M-B41 1 2.87 417.3 1064 A139-M-B42 1 3.21 378.3 1065 A139-M-B43 1 3.71 362.3 1066 A139-M-B45 1 3.71 388.3 1067 A139-M-B46 1 3.53 362.3 1068 A139-M-B48 1 3.51 360.2 1069 A139-M-B49 1 2.38 415.3 1070 A139-M-B50 1 3.29 360.2 1071 A139-M-B51 1 3.08 376.2 1072 A139-M-B52 1 3.77 382.2 1073 A139-M-B53 1 2.3 431.3 1074 A139-M-B56 1 2.28 389.3 1075 A139-M-B57 1 1.89 472.3 1076 A139-M-B58 1 2.96 453.2 1077 A139-M-B60 1 2.24 377.3 1078 A139-M-B7 1 3.13 364.2 1079 A140-M-B14 4 1.36 406.2 1080 A140-M-B22 4 1.474 412.2 1081 A140-M-B28 4 1.06 400.2 1082 A140-M-B29 4 0.846 407.1 1083 A140-M-B30 4 1.352 424.1 1084 A141-M-B14 4 1.176 418.2 1085 A141-M-B22 4 1.321 424.2 1086 A141-M-B28 4 0.932 412.2 1087 A141-M-B29 4 0.745 419.2 1088 A141-M-B30 4 1.206 436.2 1089 A142-M-B14 4 1.197 418.2 1090 A142-M-B22 4 1.345 424.2 1091 A142-M-B28 4 0.933 412.2 1092 A142-M-B29 4 0.756 419.2 1093 A142-M-B30 4 1.225 436.2 1094 A143-M-B14 4 1.45 428.2 1095 A143-M-B22 4 1.562 434.2 1096 A143-M-B28 4 1.178 422.2 1097 A143-M-B29 4 0.977 429.1 1098 A143-M-B30 4 1.443 446.1 1099 A144-M-B14 4 0.649 350.2 1100 A144-M-B22 4 0.83 356.2 1101 A144-M-B30 4 0.686 368.1 1102 A145-M-B14 4 1.52 477.1 1103 A145-M-B22 4 1.594 483.1 1104 A146-M-B14 1 3.6 408.3 1105 A146-M-B17 1 3.06 346.2 1106 A146-M-B19 1 3.07 358.2 1107 A146-M-B24 1 3.77 400.3 1108 A146-M-B25 1 3.29 360.3 1109 A146-M-B26 1 3.55 386.3 1110 A146-M-B31 1 2.97 346.2 1111 A146-M-B32 1 3.77 388.3 1112 A146-M-B33 1 2.32 464.3 1113 A146-M-B34 1 3.27 404.2 1114 A146-M-B35 1 2.88 332.2 1115 A146-M-B36 1 3.64 408.3 1116 A146-M-B37 1 3.83 408.3 1117 A146-M-B38 1 2.24 431.3 1118 A146-M-B39 1 2.17 409.3 1119 A146-M-B40 1 3.34 398.2 1120 A146-M-B41 1 2.73 429.3 1121 A146-M-B42 1 3.05 390.3 1122 A146-M-B43 1 3.57 374.3 1123 A146-M-B44 1 2.28 415.3 1124 A146-M-B45 1 3.56 400.3 1125 A146-M-B46 1 3.38 374.3 1126 A146-M-B47 1 3.58 412.3 1127 A146-M-B48 1 3.34 372.3 1128 A146-M-B49 1 2.33 427.3 1129 A146-M-B50 1 3.13 372.3 1130 A146-M-B51 1 2.92 388.3 1131 A146-M-B52 1 3.63 394.2 1132 A146-M-B53 1 2.19 443.3 1133 A146-M-B54 1 3.04 440.3 1134 A146-M-B55 1 3.11 468.3 1135 A146-M-B58 1 2.84 465.3 1136 A146-M-B7 1 2.97 376.3 1137 A147-M-B14 1 3.76 374.3 1138 A147-M-B17 1 3.2 312.3 1139 A147-M-B24 1 3.93 366.3 1140 A147-M-B25 1 3.46 326.3 1141 A147-M-B26 1 3.71 352.3 1142 A147-M-B31 1 3.12 312.3 1143 A147-M-B32 1 3.95 354.3 1144 A147-M-B33 1 2.42 430.3 1145 A147-M-B34 1 3.43 370.3 1146 A147-M-B36 1 3.76 374.3 1147 A147-M-B37 1 3.96 374.3 1148 A147-M-B39 1 2.24 375.3 1149 A147-M-B40 1 3.5 364.3 1150 A147-M-B41 1 2.86 395.3 1151 A147-M-B42 1 3.19 356.3 1152 A147-M-B43 1 3.75 340.3 1153 A147-M-B45 1 3.73 366.3 1154 A147-M-B46 1 3.55 340.3 1155 A147-M-B47 1 3.74 378.3 1156 A147-M-B48 1 3.52 338.3 1157 A147-M-B50 1 3.29 338.3 1158 A147-M-B51 1 3.08 354.3 1159 A147-M-B52 1 3.76 360.3 1160 A147-M-B54 1 3.19 406.3 1161 A147-M-B58 1 2.95 431.3 1162 A147-M-B7 1 3.12 342.3 1163 A148-M-B14 1 3.57 408.3 1164 A148-M-B17 1 3.01 346.2 1165 A148-M-B19 1 3.03 358.2 1166 A148-M-B24 1 3.72 400.3 1167 A148-M-B25 1 3.24 360.3 1168 A148-M-B26 1 3.51 386.3 1169 A148-M-B31 1 2.93 346.2 1170 A148-M-B32 1 3.74 388.3 1171 A148-M-B33 1 2.3 464.3 1172 A148-M-B34 1 3.23 404.2 1173 A148-M-B35 1 2.85 332.2 1174 A148-M-B36 1 3.59 408.3 1175 A148-M-B37 1 3.78 408.3 1176 A148-M-B39 1 2.13 409.3 1177 A148-M-B40 1 3.3 398.2 1178 A148-M-B41 1 2.69 429.3 1179 A148-M-B42 1 3.02 390.3 1180 A148-M-B43 1 3.52 374.3 1181 A148-M-B45 1 3.52 400.3 1182 A148-M-B46 1 3.35 374.3 1183 A148-M-B47 1 3.54 412.3 1184 A148-M-B48 1 3.31 372.3 1185 A148-M-B50 1 3.11 372.3 1186 A148-M-B51 1 2.9 388.3 1187 A148-M-B52 1 3.59 394.2 1188 A148-M-B53 1 2.17 443.3 1189 A148-M-B54 1 3.01 440.3 1190 A148-M-B55 1 3.07 468.3 1191 A148-M-B56 1 2.2 401.3 1192 A148-M-B58 1 2.8 465.3 1193 A148-M-B7 1 2.94 376.3 1194 A149-M-B14 1 3.83 396.2 1195 A149-M-B17 1 3.3 334.2 1196 A149-M-B19 1 3.3 346.2 1197 A149-M-B24 1 3.99 388.3 1198 A149-M-B25 1 3.53 348.2 1199 A149-M-B26 1 3.79 374.3 1200 A149-M-B31 1 3.2 334.2 1201 A149-M-B33 1 2.49 452.3 1202 A149-M-B34 1 3.49 392.2 1203 A149-M-B35 1 3.09 320.2 1204 A149-M-B36 1 3.73 396.2 1205 A149-M-B38 1 2.32 419.3 1206 A149-M-B39 1 2.29 397.2 1207 A149-M-B40 1 3.58 386.2 1208 A149-M-B41 1 2.93 417.3 1209 A149-M-B42 1 3.29 378.3 1210 A149-M-B43 1 3.81 362.3 1211 A149-M-B44 1 2.37 403.3 1212 A149-M-B45 1 3.78 388.3 1213 A149-M-B46 1 3.58 362.3 1214 A149-M-B47 1 3.81 400.2 1215 A149-M-B48 1 3.59 360.2 1216 A149-M-B49 1 2.44 415.3 1217 A149-M-B50 1 3.36 360.2 1218 A149-M-B51 1 3.15 376.2 1219 A149-M-B52 1 3.83 382.2 1220 A149-M-B53 1 2.29 431.3 1221 A149-M-B54 1 3.26 428.3 1222 A149-M-B55 1 3.34 456.3 1223 A149-M-B56 1 2.32 389.3 1224 A149-M-B57 1 1.92 472.3 1225 A149-M-B58 1 3.02 453.2 1226 A149-M-B60 1 2.27 377.3 1227 A150-M-B14 1 3.88 394.2 1228 A150-M-B17 1 3.38 332.2 1229 A150-M-B19 1 3.38 344.2 1230 A150-M-B24 1 4.05 386.3 1231 A150-M-B25 1 3.6 346.2 1232 A150-M-B26 1 3.83 372.2 1233 A150-M-B31 1 3.29 332.2 1234 A150-M-B32 1 4.04 374.3 1235 A150-M-B33 1 2.59 450.3 1236 A150-M-B35 1 3.2 318.2 1237 A150-M-B36 1 3.89 394.2 1238 A150-M-B37 1 4.06 394.2 1239 A150-M-B38 1 2.39 417.3 1240 A150-M-B39 1 2.35 395.2 1241 A150-M-B40 1 3.65 384.2 1242 A150-M-B41 1 3.04 415.2 1243 A150-M-B42 1 3.35 376.2 1244 A150-M-B43 1 3.86 360.2 1245 A150-M-B45 1 3.85 386.3 1246 A150-M-B46 1 3.68 360.2 1247 A150-M-B48 1 3.65 358.2 1248 A150-M-B49 1 2.51 413.3 1249 A150-M-B50 1 3.43 358.2 1250 A150-M-B51 1 3.23 374.2 1251 A150-M-B52 1 3.89 380.2 1252 A150-M-B53 1 2.38 429.3 1253 A150-M-B54 1 3.34 426.3 1254 A150-M-B55 1 3.39 454.3 1255 A150-M-B56 1 2.44 387.3 1256 A150-M-B57 1 1.98 470.3 1257 A150-M-B58 1 3.11 451.2 1258 A150-M-B59 1 2.41 401.3 1259 A150-M-B7 1 3.28 362.2 1260 A151-M-B14 1 3.72 396.2 1261 A151-M-B17 1 3.18 334.2 1262 A151-M-B19 1 3.18 346.2 1263 A151-M-B24 1 3.89 388.3 1264 A151-M-B25 1 3.42 348.2 1265 A151-M-B26 1 3.68 374.3 1266 A151-M-B31 1 3.09 334.2 1267 A151-M-B32 1 3.9 376.3 1268 A151-M-B33 1 2.41 452.3 1269 A151-M-B35 1 2.99 320.2 1270 A151-M-B36 1 3.84 396.2 1271 A151-M-B37 1 3.91 396.2 1272 A151-M-B38 1 2.23 419.3 1273 A151-M-B39 1 2.2 397.2 1274 A151-M-B41 1 2.83 417.3 1275 A151-M-B42 1 3.17 378.3 1276 A151-M-B43 1 3.72 362.3 1277 A151-M-B45 1 3.69 388.3 1278 A151-M-B46 1 3.51 362.3 1279 A151-M-B48 1 3.48 360.2 1280 A151-M-B49 1 2.34 415.3 1281 A151-M-B50 1 3.25 360.2 1282 A151-M-B51 1 3.05 376.2 1283 A151-M-B52 1 3.74 382.2 1284 A151-M-B53 1 2.23 431.3 1285 A151-M-B54 1 3.16 428.3 1286 A151-M-B56 1 2.24 389.3 1287 A151-M-B57 1 1.86 472.3 1288 A151-M-B58 1 2.93 453.2 1289 A151-M-B59 1 2.24 403.3 1290 A151-M-B60 1 2.21 377.3 1291 A151-M-B7 1 3.07 364.2 1292 A152-M-B14 1 3.95 352.3 1293 A152-M-B17 1 3.42 290.3 1294 A152-M-B19 1 3.43 302.3 1295 A152-M-B24 1 4.12 344.3 1296 A152-M-B25 1 3.66 304.3 1297 A152-M-B26 1 3.92 330.3 1298 A152-M-B31 1 3.32 290.3 1299 A152-M-B32 1 4.13 332.3 1300 A152-M-B33 1 2.69 408.3 1301 A152-M-B34 1 3.63 348.3 1302 A152-M-B35 1 3.23 276.3 1303 A152-M-B36 1 3.95 352.3 1304 A152-M-B37 1 4.15 352.3 1305 A152-M-B38 1 2.42 375.3 1306 A152-M-B39 1 2.49 353.3 1307 A152-M-B40 1 3.69 342.3 1308 A152-M-B41 1 3.04 373.3 1309 A152-M-B42 1 3.4 334.3 1310 A152-M-B43 1 3.95 318.3 1311 A152-M-B45 1 3.91 344.3 1312 A152-M-B46 1 3.74 318.3 1313 A152-M-B47 1 3.9 356.3 1314 A152-M-B48 1 3.72 316.3 1315 A152-M-B49 1 2.52 371.3 1316 A152-M-B50 1 3.49 316.3 1317 A152-M-B51 1 3.28 332.3 1318 A152-M-B52 1 3.96 338.3 1319 A152-M-B53 1 2.46 387.4 1320 A152-M-B54 1 3.38 384.3 1321 A152-M-B55 1 3.44 412.4 1322 A152-M-B56 1 2.42 345.3 1323 A152-M-B57 1 1.99 428.4 1324 A152-M-B58 1 3.14 409.3 1325 A152-M-B7 1 3.33 320.3 1326 A153-M-B48 1 3.64 350.3 1327 A154-M-B14 1 3.34 324.3 1328 A154-M-B17 1 2.58 262.2 1329 A154-M-B19 1 2.6 274.2 1330 A154-M-B24 1 3.54 316.3 1331 A154-M-B25 1 2.9 276.3 1332 A154-M-B26 1 3.25 302.3 1333 A154-M-B31 1 2.46 262.2 1334 A154-M-B32 1 3.53 304.3 1335 A154-M-B33 1 2 380.3 1336 A154-M-B34 1 2.88 320.2 1337 A154-M-B35 1 2.32 248.2 1338 A154-M-B36 1 3.29 324.3 1339 A154-M-B42 1 2.63 306.3 1340 A154-M-B43 1 3.29 290.3 1341 A154-M-B45 1 3.27 316.3 1342 A154-M-B47 1 3.25 328.3 1343 A154-M-B48 1 2.99 288.3 1344 A154-M-B49 1 1.85 343.3 1345 A154-M-B51 1 2.45 304.3 1346 A154-M-B52 1 3.32 310.2 1347 A154-M-B53 1 1.83 359.3 1348 A154-M-B54 1 2.65 355.2 1349 A154-M-B55 1 2.73 384.3 1350 A154-M-B58 1 2.38 381.3 1351 A154-M-B7 1 2.49 292.3 1352 A155-M-B17 1 2.03 323.2 1353 A155-M-B19 1 2.05 335.2 1354 A155-M-B25 1 2.28 337.3 1355 A155-M-B31 1 2 323.2 1356 A155-M-B32 1 2.9 365.3 1357 A155-M-B33 1 1.86 441.3 1358 A155-M-B35 1 1.87 309.2 1359 A155-M-B36 1 2.71 385.3 1360 A155-M-B39 1 1.72 386.3 1361 A155-M-B40 1 2.37 375.2 1362 A155-M-B43 1 2.61 351.3 1363 A155-M-B45 1 2.66 377.3 1364 A155-M-B53 1 1.74 420.3 1365 A155-M-B7 1 2.02 353.3 1366 A156-M-B24 1 3.19 403.3 1367 A156-M-B34 1 2.59 407.2 1368 A156-M-B37 1 3.23 411.3 1369 A156-M-B45 1 2.96 403.3 1370 A156-M-B49 1 2.01 430.3 1371 A156-M-B51 1 2.21 391.3 1372 A156-M-B52 1 2.94 397.3 1373 A156-M-B54 1 2.4 443.3

When R1 is a substituent with a chiral center the compounds obtained were mixture of diastereoisomers and they were separed by preparative HPLC.

When the diastereoisomers are resolved, the chirality is to be intended on the 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one scaffold.

Working in a parallel manner, the following compounds were prepared:

HPLC HPLC Entry Compound ¹H NMR (400 MHz, DMSO-d₆) Method r.t. min. [M + H]⁺ 1374 A157-M-B65 δ = 8.50 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 5.4 Hz, 4 1.196 408.2 isomer S 1H), 7.83 (br. s., 1H), 7.44 (d, J = 1.7 Hz, 1H), 7.28 (s, 1H), 5.08-5.17 (m, 1H), 4.61-4.75 (m, 1H), 3.73 (dd, J = 13.1, 4.0 Hz, 1H), 3.36-3.46 (m, 1H), 3.10-3.18 (m, 1H), 2.90-3.04 (m, 1H), 2.68-2.84 (m, 2H). 1375 A157-M-B65 δ = 8.61 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 5.4 Hz, 4 1.224 408.2 isomer R 1H), 7.68 (d, J = 1.7 Hz, 1H), 5.11 (td, J = 8.9, 4.6 Hz, 1H), 4.63-4.72 (m, 1H), 2.78 (d, J = 6.7 Hz, 2H) 1376 A133-M-B61 4 1.373 464.2 isomer R 1377 A127-M-B61 4 1.332 414.2 isomer R 1378 A157-M-B161 8.41-8.60 (m, 1H), 6.90-8.36 (m, 5H), 4 1.052 415.2 isomer R 4.71 (dd, J = 33.3, 3.3 Hz, 2H), 3.56-3.82 (m, 1H), 2.61-2.82 (m, 2H), 1.37-1.75 (m, 2H), 0.80-1.23 (m, 10H) 1379 A158-M-B61 4 1.238 432.2 isomer R 1380 A133-M-B61 7.54 (t, J = 7.7 Hz, 1H), 7.45 (d, J = 1.8 Hz, 4 1.375 464.2 isomer S 1H), 7.16 (d, J = 1.7 Hz, 1H), 4.69 (sxt, J = 4.2 Hz, 1H), 4.49 (br. s., 1H), 3.72 (dd, J = 13.0, 4.1 Hz, 1H), 3.59 (dq, J = 8.9, 5.8 Hz, 1H), 2.82 (dd, J = 14.9, 8.7 Hz, 1H), 2.57 (dd, J = 14.5, 5.4 Hz, 1H) 1381 A127-M-B61 7.68 (d, J = 3.4 Hz, 1H), 7.63 (d, J = 9.2 Hz, 4 1.363 414.2 isomer S 1H), 7.28-7.42 (m, 4H), 7.09 (d, J = 1.8 Hz, 1H), 6.90-6.99 (m, 1H), 4.61-4.72 (m, 1H), 4.50 (t, J = 5.4 Hz, 1H), 3.69 (ddd, J = 13.0, 4.2, 1.2 Hz, 1H), 3.60 (dq, J = 9.2, 5.8 Hz, 1H), 2.79 (dd, J = 14.6, 8.4 Hz, 1H), 2.58 (dd, J = 14.8, 5.8 Hz, 1H) 1382 A133-M-B62 7.60 (d, J = 1.7 Hz, 1H), 7.17 (d, J = 1.8 Hz, 4 1.426 458.2 isomer R 1H), 4.89 (dt, J = 7.9, 6.3 Hz, 1H), 4.73-4.95 (m, 1H), 4.59-4.69 (m, 1H), 2.83 (dd, J = 14.8, 6.5 Hz, 1H), 2.74 (dd, J = 14.9, 7.2 Hz, 1H) 1383 A127-M-B62 8.49 (d, J = 8.3 Hz, 1H), 7.47 (d, J = 1.8 Hz, 4 1.092 408.2 isomer R 1H), 7.08 (d, J = 1.8 Hz, 1H), 6.91-7.00 (m, 1H), 4.82-4.94 (m, 1H), 4.62 (dd, J = 9.5, 2.8 Hz, 1H), 3.57-3.66 (m, 1H), 3.50 (d, J = 6.0 Hz, 2H), 2.68-2.83 (m, 2H) 1384 A157-M-B62 8.51 (d, J = 8.3 Hz, 1H), 8.11 (d, J = 5.4 Hz, 4 409.2 1.003 isomer R 1H), 7.72 (d, J = 1.8 Hz, 1H), 7.18-7.27 (m, 1H), 4.84-4.93 (m, 1H), 4.61-4.72 (m, 1H), 3.64 (d, J = 5.2 Hz, 1H), 3.34 (br. s., 1H), 2.69-2.87 (m, 2H) 1385 A158-M-B62 8.45 (d, J = 8.2 Hz, 1H), 7.76 (br. s., 1H), 4 1.109 426.2 isomer R 7.55 (ddd, J = 9.8, 6.3, 3.2 Hz, 1H), 7.45-7.50 (m, 1H), 7.26-7.34 (m, 5H), 7.18-7.25 (m, 1H), 7.13-7.16 (m, 1H), 6.99-7.08 (m, 1H), 4.82-4.90 (m, 1H), 4.79 (br. s., 1H), 4.68 (s, 1H), 3.65 (dd, J = 9.0, 1.8 Hz, 1H), 3.50 (br. s., 2H), 3.37 (d, J = 2.3 Hz, 9H), 2.68-2.85 (m, 2H) 1386 A133-M-B62 8.41 (d, J = 8.3 Hz, 1H), 7.41 (d, J = 1.8 Hz, 4 1.332 458.2 isomer S 1H), 7.15-7.18 (m, 1H), 4.79-4.90 (m, 2H), 4.66 (br. s., 1H), 3.68 (d, J = 1.2 Hz, 1H), 3.45-3.61 (m, 1H), 3.34-3.43 (m, 1H), 2.79-2.88 (m, 1H), 2.70 (dd, J = 15.0, 6.8 Hz, 1H) 1387 A127-M-B62 8.43 (d, J = 8.3 Hz, 1H), 7.08 (d, J = 1.8 Hz, 4 1.121 408.2 isomer S 1H), 7.03-7.43 (m, 11H), 6.93-7.01 (m, J = 5.1, 4.0, 0.9, 0.9, 0.9 Hz, 1H), 4.88 (q, J = 6.0 Hz, 1H), 4.64 (q, J = 3.3 Hz, 1H), 3.62-3.71 (m, 2H), 3.55 (dd, J = 7.4, 5.5 Hz, 2H), 3.34 (br. s., 2H), 2.65-2.73 (m, 1H) 1388 A133-M-B63 7.85 (br. s., 1H), 7.65 (br. s., 2H), 7.49 (s, 4 1.173 497.2 Unresolved 2H), 7.36 (br. s., 2H), 7.17 (s, 2H), 4.75 (br. mixture of diast. s., 1H), 2.18 (s, 1H), 2.07 (s, 1H), 1.96 (s, 1H), 1.75 (s, 1H), 1.63 (s, 7H), 1.23 (br. s., 2H), 0.14-0.34 (m, 2H) 1389 A127-M-B63 7.59 (d, J = 1.1 Hz, 1H), 7.49 (s, 1H), 4 1.02 447.2 unresolved 7.40 (br. s., 2H), 5.44-6.15 (m, J = 155.3 Hz, 1H), mixture of diast. 4.33-5.20 (m, 1H), 4.17 (dd, J = 13.4, 11.8 Hz, 1H), 3.67-3.94 (m, 1H), 2.80 (d, J = 16.4 Hz, 1H), 0.15-0.35 (m, 1H) 1390 A157-M-B63 4 0.782 448.2 unresolved mixture of diast. 1391 A158-M-B63 7.13-7.40 (m, 1H), 3.28-3.58 (m, 16H), 4 1.031 465.2 P26 unresolved 3.08-3.28 (m, 1H), 2.41-2.60 (m, 5H) mixture of diast. 1392 A133-M-B64 7.96 (s, 1H), 7.36-7.90 (m, 1H), 4 1.44 472.2 isomer R 7.12-7.31 (m, 1H), 7.09-7.39 (m, 1H), 4.54 (s, 1H), 3.95 (d, J = 4.9 Hz, 1H), 3.53 (br. s., 1H), 3.33 (s, 13H), 3.15-3.41 (m, 1H), 3.08-3.29 (m, 1H), 2.52-2.90 (m, 1H), 2.41-2.62 (m, 4H) 1393 A127-M-B64 8.00 (d, J = 8.4 Hz, 1H), 7.65 (br. s., 1H), 4 1.148 422.2 isomer R 7.39-7.41 (m, 1H), 7.24-7.30 (m, 2H), 7.18-7.22 (m, 2H), 7.08 (d, J = 1.8 Hz, 1H), 6.92-7.00 (m, 1H), 4.53 (s, 1H), 3.93 (br. s., 1H), 3.51 (s, 3H), 2.53-2.93 (m, 4H) 1394 A157-M-B64 8.10 (d, J = 5.4 Hz, 1H), 7.94 (d, J = 8.5 Hz, 4 0.92 423.2 isomer R 1H), 7.73 (br. s., 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.44-7.54 (m, 1H), 7.27 (d, J = 1.8 Hz, 1H), 4.56 (br. s., 1H), 3.92 (br. s., 1H), 3.49-3.60 (m, 1H), 3.26-3.38 (m, 1H), 3.23 (br. s., 1H), 3.16 (s, 1H), 2.82 (s, 1H), 2.65 (s, 1H), 2.48-2.56 (m, 4H) 1395 A158-M-B64 7.94 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 1.8 Hz, 4 1.331 472.2 isomer S 1H), 7.15-7.16 (m, 1H), 7.14-7.20 (m, 2H), 7.09-7.13 (m, 2H), 7.03-7.08 (m, 1H), 4.77 (t, J = 5.5 Hz, 1H), 4.56 (br. s., 1H), 3.87-3.99 (m, 1H), 3.56-3.63 (m, 1H), 2.54-2.80 (m, 4H) 1396 A127-M-B64 6.91-7.00 (m, 1H), 4.50-4.59 (m, J = 7.1, 4 1.181 422.2 isomer S 3.4, 3.4 Hz, 1H), 3.89-3.99 (m, J = 5.9 Hz, 1H), 3.53-3.63 (m, J = 13.6, 3.2 Hz, 1H), 2.76 (dd, J = 13.5, 5.7 Hz, 1H), 2.62-2.70 (m, 1H), 2.52-2.62 (m, 2H) 1397 A133-M-B65 8.62 (d, J = 8.5 Hz, 1H), 8.49 (d, J = 8.4 Hz, 4 1.571 457.2 isomer S 1H), 7.81-8.00 (m, 2H), 7.75 (d, J = 7.9 Hz, 2H), 5.00-5.18 (m, J = 2.7 Hz, 1H), 4.60-4.75 (m, J = 4.3 Hz, 1H) 1398 A127-M-B65 8.62 (d, J = 8.4 Hz, 1H), 8.50 (d, J = 8.7 Hz, 4 1.44 407.2 isomer S 1H), 7.89 (br. s., 3H), 7.73 (br. s., 1H), 5.05-5.22 (m, J = 3.5 Hz, 1H), 4.58-4.72 (m, J = 6.9, 6.9, 3.3 Hz, 1H) 1399 A158-M-B65 8.58 (d, J = 8.3 Hz, 1H), 8.45 (d, J = 8.3 Hz, 4 1.451 425.2 isomer S 1H), 5.02-5.26 (m, J = 9.0, 4.6, 4.6 Hz, 1H), 4.63-4.77 (m, 1H) 

1. A compound of formula (I)

wherein: R1 is —NR^(a)R^(b) or —OR^(a) and R2 is —NH₂, —NHCOR^(c), —NHCONHR^(c), —NHSO₂R^(c), —C≡CR^(d) or R^(d) wherein R^(a), R^(b), R^(c) and R^(d), are each independently hydrogen or a group optionally further substituted, selected from straight or branched C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, cycloalkyl C₁-C₆ alkyl, heterocyclyl, heterocyclyl C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, heteroaryl and heteroaryl C₁-C₆ alkyl, or R^(a) and R^(b), taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH; said 3 to 7 membered heterocyclyl or heteroaryl can be optionally substituted by C₁-C₆ alkyl, heteroaryl, aminocarbonyl, C₂-C₆ alkenyl, heterocyclyl, alkylsulfonyl or aryl; wherein R^(a) is optionally substituted by halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, dialkylamino, hydroxyl or alkoxy; R^(b) is optionally substituted by halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, dialkylamino, hydroxyl or alkoxy; R^(c) is optionally substituted by halogen, oxo groups (═O), cyano, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, heterocyclyl, aryl, heteroaryl, dialkylamino or alkoxy; and R^(d) is optionally substituted by halogen, nitro, carboxy, cyano, C₁-C₆ alkyl, polyfluorinated alkyl, C₃-C₆ cycloalkyl, aryl, heteroaryl, amino, dialkylamino, hydroxyl, alkoxy, polyfluorinated alkoxy, carbonyl, alkylcarbonyl, alkoxycarbonyl or alkylthio; and pharmaceutically acceptable salts thereof.
 2. A compound of formula (I) according to claim 1 wherein: R1 is —NR^(a)R^(b) and R^(a) and R^(b) are both hydrogen atoms or one of them is a hydrogen atom and the remaining one of R^(a) or R^(b) is a straight or branched C₁-C₆ alkyl or C₂-C₆ alkenyl group or it is an optionally substituted aryl or aryl C₁-C₆ alkyl group, optionally substituted by C₁-C₆ alkyl, halogen, hydroxy or aminio.
 3. A compound of formula (I) according to claim 1 or 2, wherein: R2 is —NHCOR^(c).
 4. A compound of formula (I) according to claim 1 or 2, wherein: R2 is —NHCONHR^(c).
 5. A compound of formula (I) according to claim 1 or 2, wherein: R2 is —NHSO₂R^(c).
 6. A compound of formula (I) according to claim 1 or 2 wherein R2 is a fragment denoted by any of codes A1-A22 and A24-A158 and R1 is a fragment denoted by any of codes B1-B65, wherein M is

Fragment CODE

A1

A2

A3

A4

A5

A6

A7

A8

A9

A10

A11

A12

A13

A14

A15

A16

A17

A18

A19

A20

A21

A22

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A45

A46

A47

A48

A49

A50

A51

A52

A53

A54

A55

A56

A57

A58

A59

A60

A61

A62

A63

A64

A65

A66

A67

A68

A69

A70

A71

A72

A73

A74

A75

A76

A77

A78

A79

A80

A81

A82

A83

A84

A85

A86

A87

A88

A89

A90

A91

A92

A93

A94

A95

A96

A97

A98

A99

A100

A101

A102

A103

A104

A105

A106

A107

A108

A109

A110

A111

A112

A113

A114

A115

A116

A117

A118

A119

A120

A121

A122

A123

A124

A125

A126

A127

A128

A129

A130

A131

A132

A133

A134

A135

A136

A137

A138

A139

A140

A141

A142

A143

A144

A145

A146

A147

A148

A149

A150

A151

A152

A153

A154

A155

A156

A157

A158

B1

B2

B3

B4

B5

B6

B7 B8

B9

B10

B11

B12

B13

B14

B15

B16

B17

B18

B19

B20

B21

B22 B23

B24

B25

B26

B27

B28

B29

B30

B31

B32

B33

B34

B35

B36

B37

B38

B39

B40

B41

B42

B43

B44

B45

B46

B47

B48

B49

B50

B51

B52

B53

B54

B55

B56

B57

B58

B59

B60

B61

B62

B63

B64

B65.


7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined in claim 1 and, at least, one pharmaceutically acceptable excipient, carrier and/or diluent. 